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SUMMARY 
The dysregulation of the brain serotonergic system has been 
implicated in many neuropsychiatric disorders, including depression 
and schizophrenia, and thus is a common target for therapy. 
Tryptophan hydroxylases (TPH) are the rate-limiting enzymes that 
catalyze the biosynthesis of serotonin, which is the neurotransmitter 
involved in serotonergic signaling. TPH is present in the body as two 
isoforms. Tryptophan hydroxylase-1 (TPH1) is found mainly in 
peripheral tissues, while the more recently discovered tryptophan 
hydroxylase-2 (TPH2) is neuronal specific and controls brain serotonin 
synthesis. Initial efforts to characterize TPH2 have revealed that the 
enzyme is unstable in vitro, as compared to TPH1. However, the 
mechanisms involved in the regulation of TPH2 stability are yet to be 
elucidated. As such, the objective of this work is to examine the 
regulatory mechanisms that underlie the instability of TPH2 on a 
molecular level. In particular, we sought to identify novel regulatory 
partners that may be involved in the regulation of TPH2 stability. 
Furthermore, we investigated the role of the ubiquitin proteasome 
pathway in the degradation of TPH2, which may also affect its stability 
in vitro.  
 
 The present study has identified heat shock protein HSP70 as a 
novel protein interacting partner of both TPH1 and TPH2. HSP70 is 
observed to interact more strongly with TPH1 than with TPH2. We also 
	   ix	  
determined that interaction with HSP70 occurs through a non-
conserved region of 10 amino acids within the N-terminal regulatory 
domains of TPH1 and TPH2. Functionally, our findings suggest that 
HSP70 can positively regulate TPH protein stability and expression. 
Furthermore, TPH2 is observed to be more sensitive to changes in 
levels of endogenous HSP70, as compared to TPH1, which indicated 
that the instability of TPH2 is partly due to its poor interaction with 
HSP70. We have also demonstrated, for the first time, that TPH2 can 
be ubiquitinated and degraded via the proteasome. Mutagenesis 
studies have also revealed that lysine-less TPH2 can still undergo 
ubiquitination, indicating that TPH2 may be ubiquitinated through 
alternative mechanisms.  
 
Taken together, the results presented in this work have revealed 
previously undiscovered regulatory mechanisms that are involved in 
the regulation of TPH2 stability. These findings contribute to the 
understanding of the physiological regulation of the brain serotonergic 
system, which in turn can advance the development of new therapeutic 
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1.  INTRODUCTION 
 Psychiatric disorders are one of the most pressing public health 
issues faced by the global population today. Indeed, the World Health 
Organization has reported that in 2004 mental disorders represent 13% 
of the global burden of disease, exceeding even cancer and 
cardiovascular diseases. In particular, depression, which affects 11% 
of the global population, alone accounted for 4.3% of the global burden 
of disease (Mathers, Fat et al. 2008; Collins, Patel et al. 2011). In 2012, 
about 18.6% of the adult population in the United States are affected by 
mental illnesses (SAMHSA 2013), while in Singapore, about 10% of the 
adult population are affected (Chong, Abdin et al. 2012). These 
debilitating conditions have a significant impact on both the global 
economy and individuals, and extensive research has been carried out 
over the years to develop treatments for these disorders. 
 
 The relationship between serotonergic signaling and 
neuropsychiatric disorders first emerged when monoamine oxidase 
inhibitors were shown to abolish the effects of depression (Bueno and 
Himwich 1967; Ban 2001). Over the years, the role of serotonin, in 
addition to the involvement of other monoamines such as dopamine 
and norepinephrine, in the pathophysiology of mental disorders has 
become more established (Ruhe, Mason et al. 2007). The serotonergic 
system, together with the other monoamine systems, is also a common 
target for many current treatments of neuropsychiatric conditions (Chen 
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and Skolnick 2007; Krishnan 2007). Nevertheless, the mechanisms by 
which serotonergic dysregulation can give rise to mental disorders are 
still not fully understood. As such, much effort has been placed into 
studying the workings of the serotonergic system, on both systemic 
and molecular levels, which in turn can also provide new insights into 
the development of new therapeutic drugs in the treatment of these 
disorders. 
  
1.1 THE BRAIN SEROTONERGIC SYSTEM   
 The serotonergic system in the human body mainly regulates 
physiological functions in the gastrointestinal tract, blood, and central 
nervous system (CNS). Signaling within the system is carried out by 
the monoamine neurotransmitter serotonin (5-hydroxytryptamine, 5-
HT), which in turn gives rise to changes in physiological processes. As 
the serotonergic system of the CNS has been implicated to play an 
imperative role in the pathophysiology of neuropsychiatric disorders, 
the focus of this work will be on the brain serotonergic system rather 
the peripheral serotonergic system.  
 
1.1.1 Structure of the brain serotonergic system 
In order to better understand its functions, the structure of the 
brain serotonergic system will be first elaborated. The actions of the 
brain serotonergic system are carried out by an intricate network, which 
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includes 5-HT synthesis, 5-HT receptor signaling, and 5-HT reuptake 
by transporters (Figure 1.1, A and B).   
 
1.1.1.1 Serotonergic neurons within the brain 
 The cell bodies of serotonergic neurons are found on or near the 
midline of the brain stem, organized in clusters known as the raphe 
nuclei. They can be further separated into two groups, according to 
their projections within the brain (Figure 1.1B). The superior or rostral 
group mainly comprises of the caudal linear nucleus, median raphe 
nucleus, dorsal raphe nucleus, and B9 neurons dorsal of the medial 
lemniscus. On the other hand, the inferior or caudal group is made up 
of the nucleus raphe obscurus,	  nucleus raphe pallidus, nucleus raphe 
magnus and neurons from the lateral reticular formation. Raphe nuclei 
in the rostral group receive afferent inputs primarily from the limbic 
system within the forebrain. In turn, serotonergic fibers originating from 
the rostral group project to brain areas that perform higher function, 
such as the forebrain, cerebral cortex, hippocampus, hypothalamus, 
and thalamus. Afferent inputs to the caudal group can originate from 
the hypothalamus, thalamus, amygdala and the reticular formation of 
the medulla. Consequently, serotonergic projections from the caudal 
group can innervate the brain stem and spinal cord (Dahlström and 
Fuxe 1964; Jacobs and Azmitia 1992; Hornung 2003). 
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FIGURE 1.1. The brain serotonergic system. A, The 5-HT network at 
the synapse. 5-HT is synthesized by tryptophan hydroxylase within the 
serotonergic neurons and stored in vesicles, before being released into 
the synaptic cleft. Extracellular 5-HT can then associate with pre- or 
post-synaptic 5-HT receptors to bring about physiological changes (1 
and 2). 5-HT reuptake is mediated by the serotonin transporter, which 
transports 5-HT back into the serotonergic neurons, where it is broken 
down by monoamine oxidase (3). (Image from (aan het Rot, Mathew et 
al. 2009)). B, Serotonergic projections from the raphe nuclei in the 
brain stem are highlighted in light blue. Efferent projections from the 
rostral group, including the dorsal raphe nuclei, innervate regions of the 
brain performing higher function, while serotonergic fibers from the 
caudal group project to the brain stem and spinal cord. (Image from 
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1.1.1.2 Serotonin receptors 
 Serotonergic neurotransmission is mediated by 5-HT receptors, 
which are activated when bound to 5-HT released from serotonergic 
neurons. This in turn leads to the activation of other downstream 
signaling cascades.  To date, there are seven known families of 5-HT 
receptors, with a total of fourteen subtypes, which have specific pre- 
and post-synaptic localizations. While the 5-HT3 receptor is a ligand-
gated ion channel, most 5-HT receptors are members of the seven 
transmembrane G-protein coupled receptor family. As such, they can 
bring about excitatory or inhibitory responses, depending on the 
coupled G-protein (Nichols and Nichols 2008). Given their essential 
roles in the brain serotonergic system, 5-HT receptors can influence a 
wide range of biological and behavioral processes. Thus, 5-HT 
receptors are potential targets for therapeutic drugs, such as 
antidepressants and antipsychotics (Glennon 1987; Nichols and 
Nichols 2008; Meltzer, Massey et al. 2012).  
 
1.1.1.3 Termination of serotonergic actions 
 5-HT released into the synapse is removed by a specialized 
serotonin transporter protein (SERT), which is a 12 transmembrane, 
sodium- and chloride-dependent transporter, resulting in the 
termination of serotonergic action. As the amount of extracellular 5-HT 
within the synaptic cleft can influence 5-HT signaling, 5-HT reuptake by 
SERT can also modulate 5-HT neurotransmission and bring about 
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changes in behavior or homeostasis. It is on this basis that SERT has 
also become a pharmacological target for many selective serotonin 
reuptake inhibitors (SSRIs), which exert their effects by modulating the 
amount of extracellular 5-HT present (White, Walline et al. 2005; 
Nichols and Nichols 2008). 
 
1.1.2 Functions of the brain serotonergic system 
 In the brain, the serotonergic system is predominantly involved 
in the modulation of higher order behavioral functions, such as mood, 
sleep, circadian rhythm, appetite, aggression, sexual behavior, as well 
as cognitive functions such as learning and memory (Simansky 1996; 
Lucki 1998; Canli and Lesch 2007). The dysregulation of the brain 
serotonergic system may lead to the disruption of these functions. 
Indeed, pharmacological intervention of serotonergic regulation has 
been indicated to alleviate symptoms of many neuropsychiatric 
disorders, such as depression, anxiety, bipolar disorder and 
schizophrenia (Coppen 1967; Duman, Heninger et al. 1997; Mann 
1999; Meltzer, Li et al. 2003). In addition, disruptions in 5-HT synthesis, 
as well as 5-HT receptors and SERT functions, have also been 
associated with these psychiatric conditions (Hoyer, Hannon et al. 
2002; Murphy, Uhl et al. 2003; Matthes, Mosienko et al. 2010).  
 
   In addition to its role in regulating behavior, it is becoming 
increasingly evident that the brain serotonergic system is also involved 
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in adult neurogenesis within the hippocampus (Gould 1999; Brezun 
and Daszuta 2000; Banasr, Hery et al. 2003; Alenina and Klempin 
2014). This generation of new hippocampal neurons may be important 
for learning and memory. Interestingly, treatment with SSRIs has been 
shown to improve neurogenesis and synaptic plasticity (Malberg, Eisch 
et al. 2000; Wang, David et al. 2008; Chen, Pan et al. 2014). 
Furthermore, several findings have also suggested that exercise can 
induce neurogenesis, and this process may be mediated by the action 
of 5-HT (van Praag, Kempermann et al. 1999; Kronenberg, Reuter et 
al. 2003; Klempin, Beis et al. 2013). 
 
1.2 SEROTONIN 
 Central to the serotonergic system is serotonin (5-
hydroxytryptamine, 5-HT), a major monoamine neurotransmitter and 
hormone. Originally discovered in blood serum and gastric mucosa as 
an inducer of vasoconstriction and gastrointestinal contraction 
(Rapport, Green et al. 1948; Erspamer and Asero 1952), 5-HT is now 
known to play a role in a wide range of physiological functions. In order 
to advance the development of treatments for conditions in which the 
serotonergic system is disrupted, an understanding of the biosynthetic 
pathway of 5-HT and regulatory mechanisms involved is necessary.  
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1.2.1 Biosynthesis and metabolism 
 5-HT is synthesized by a two-step biochemical pathway (Tyce 
1990) (Figure 1.2). L-tryptophan is first converted to 5-
hydroxytryptophan (5-HTP) by the enzyme tryptophan hydroxylase 
(TPH). This TPH-mediated reaction is also the rate-limiting step in the 
synthesis of 5-HT. In the second step of the process, 5-HTP is 
converted by L-aromatic amino acid decarboxylase to form 5-HT in a 
decarboxylation reaction. Subsequently, 5-HT can be broken down by 
oxidative deamination to produce 5-hydroxyindoleacetic acid (5-HIAA), 
in a reaction catalyzed by monoamine oxidases (MAO), particularly 
MAO-A.   
 
 1.2.2 Tryptophan hydroxylase 
 Tryptophan hydroxylase (TPH) belong to a family of aromatic 
amino acid hydroxylases, together with tyrosine hydroxylase (TH) and 
phenylalanine hydroxylase (PAH) (Figure 1.3). Similar to the other two 
enzymes, TPH consists of an N-terminal regulatory domain, a central 
catalytic domain, and a C-terminal tetramerization domain (Fitzpatrick 
1999). The presence of its C-terminal domain allows TPH to exist 
under physiological conditions as a homotetramer, which is required for 
the functionality of the enzyme. In addition, TPH is a 
tetrahydrobiopterin (BH4)-dependent enzyme. As such, TPH also 
requires the BH4 cofactor and iron to bring about enzymatic activity 
(Fitzpatrick 2003). In members of the aromatic amino acid hydroxylase  
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FIGURE 1.2. Serotonin synthesis pathway. TPH converts L-
tryptophan into 5-HTP in the first, rate-limiting step. 5-HTP is then 
decarboxylated by AADC to form 5-HT in the second step. 5-HT can be 
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FIGURE 1.3. Aromatic amino acid hydroxylases. Domain structures 
and sequences of rat PAH, TH and TPH are compared. Regulatory 
domains are denoted in blue, catalytic domains in red, and 
tetramerization domains in yellow. Phosphorylation sites within the 
regulatory domains, which play a role in differential regulation of protein 
expression and activity, are represented as vertical lines (Adapted from 
(Fitzpatrick 1999)). ClustalW sequence alignment of the amino acid 
sequences of rat PAH, TH and TPH revealed that the N-terminal 
regulatory domains are divergent in length and sequence, while the 
catalytic and tetramerization domains are more homologous. 
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family, amino acid sequences within the catalytic and C-terminal 
domains are relatively homologous. The C-terminal domains also form 
conserved hydrophobic coiled-coil motifs, or leucine zippers, that 
facilitate the formation of homotetramers (Liu and Vrana 1991; Vrana, 
Walker et al. 1994; Knappskog, Flatmark et al. 1996; Carkaci-Salli, 
Flanagan et al. 2006). However, their regulatory domains share very 
little similarities, in both sequence and structure, which may give rise to 
differences in substrate specificities as well as unique regulatory 
characteristics (Figure 1.3). This dissimilarity is also evident between 
the two isoforms of TPH. 
 
1.2.2.1 Tryptophan hydroxylase 1 
 Tryptophan hydroxylase 1 (TPH1) was first described and 
characterized in the 1960s (Grahame-Smith 1964; Lovenberg, Jequier 
et al. 1967; Jequier, Robinson et al. 1969). The gene consists of 11 
exons, and was mapped to chromosome 11 and chromosome 7 in 
human and mouse, respectively (Ledley, Grenett et al. 1987; Stoll, 
Kozak et al. 1990; Stoll and Goldman 1991; Nielsen, Dean et al. 1992). 
TPH1 is mainly expressed in peripheral tissues, namely intestinal 
enterochromaffin cells, blood platelets, beta cells of the islets of 
Langerhans, as well as the pineal gland (Côté, Thévenot et al. 2003; 
Kim, Toyofuku et al. 2010). Nevertheless, TPH1 is also detected in 
neuronal tissues, albeit in low levels (Patel, Pontrello et al. 2004; 
Gundlah, Alves et al. 2005; Malek, Dardente et al. 2005; Zill, Buttner et 
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al. 2007). About 95% of the 5-HT in the body is present in the 
periphery, particularly in the gastrointestinal tract, where it serves to 
regulate peristaltic movements and intestinal secretion. 5-HT can also 
be stored in platelets, where it regulates vascular tone. Peripheral 5-HT 
has also been indicated to play a role in cardiac morphorgenesis during 
prenatal development (Yavarone, Shuey et al. 1993). Within the pineal 
gland, 5-HT acts as an intermediate in the biosynthesis of melatonin, 
which in turn is involved in the control of circadian rhythm (Reiter 
1991).  
 
1.2.2.2 Tryptophan hydroxylase 2 
 TPH has long been considered to exist as a single isoform and 
extensively studied as such. However, when TPH1 was ablated in 
mice, levels of 5-HT within the brain was observed to remain relatively 
unchanged. This lead to the identification of a second isoform of TPH, 
tryptophan hydroxylase 2 (TPH2) (Walther and Bader 2003; Walther, 
Peter et al. 2003). The TPH2 gene comprises of 11 exons and has 
been mapped to chromosome 12 in human, and chromosome 10 in 
mouse. TPH2 expression is primarily limited to the central nervous 
system (CNS), mainly the neurons of raphe nuclei within the brain stem 
(Côté, Thévenot et al. 2003; Walther, Peter et al. 2003; Patel, Pontrello 
et al. 2004). In humans and mice, expression of TPH2 has also been 
detected in the cortex, hippocampus and cerebellum (Zill, Buttner et al. 
2007; Gutknecht, Kriegebaum et al. 2009). As a neuronal specific 
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isoform, TPH2 controls 5-HT synthesis within the brain (Zhang, 
Beaulieu et al. 2004), which in turn plays a role in the regulation of 
behavioral functions. These include mood, stress, cognition, synaptic 
plasticity, sleep and even sexual behavior (Lucki 1998; Gutknecht, 
Kriegebaum et al. 2009). Although the expression of TPH1 and TPH2 
were thought to be mutually exclusive, subsequent studies also 
detected the expression of TPH2 in several peripheral sites in rodents, 
such as the enteric neurons in the gut, bile duct, islets of Langerhans, 
and adipose tissues (Côté, Thévenot et al. 2003; Hageman, Wagener 
et al. 2010; Schraenen, Lemaire et al. 2010; Omenetti, Yang et al. 
2011), suggesting that TPH2 may also control 5-HT signaling in the 
periphery, possibly as part of the stress response (Chen and Miller 
2013).   
 
1.2.2.3 Insights to TPH1 and TPH2 function from in vivo models 
 Studies performed using transgenic models have also further 
contributed to the understanding of functions that are controlled by 
TPH1 and TPH2 on a systemic level.  
 
Tph1 knockout mice have reduced peripheral 5-HT levels, and 
exhibit palor, fatigue and difficulties in breathing. More importantly, 
these Tph1-/- mice display functional cardiac abnormalities that can 
progressively lead to heart failure (Côté, Thévenot et al. 2003). A 
separate study has also shown that Tph1-/- mice are diabetic and have 
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disrupted insulin secretion as a result of the absence of 5-HT in the 
pancreas (Paulmann, Grohmann et al. 2009). Moreover, liver 
regeneration was observed to be impaired in partially hepatectomized 
Tph1-/- mice (Lesurtel, Graf et al. 2006). In addition, mice that are 
deficient in Tph1 in the gut (Tph1gut -/-) exhibit an increase in osteoblast 
proliferation and bone formation, resulting in severely high bone mass 
(Yadav, Ryu et al. 2008). However, this increase in bone mass is not 
observed in global knockout Tph1-/- mice, suggesting the possible 
involvement of compensatory pathways (Cui, Niziolek et al. 2011).  
 
Tph1 has also been demonstrated to play a crucial role in 
development. Both heterozygous (Tph1+/-) and homozygous (Tph1-/-) 
offsprings of Tph1-/- mice are smaller in size, and display abnormalities 
in morphology, particularly in the brain. This in turn indicated that 
maternal 5-HT may play morphogen-like role in embryonic 
development (Côté, Fligny et al. 2007). Furthermore, Tph1 is shown to 
be expressed in murine raphe at postnatal day 22, and thus may also 
be involved in the synthesis of 5-HT during the late developmental 
stages of the brain (Nakamura, Sugawara et al. 2006). Taken together, 
these studies in Tph1-/- mice have indicated that peripheral 5-HT is 
involved in development, liver regeneration, regulating insulin 
secretion, as well as controlling bone mass.  
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 The functions of Tph2 have been studied in vivo using inbred 
mouse strains with different allelic distributions of the SNP C1473G, 
which encodes for a missense mutation P447R in Tph2 that causes a 
reduction in its activity (Zhang, Beaulieu et al. 2004). The allelic 
differences have been demonstrated to give rise to behavioral 
changes, with mice homozygous for the 1473G allele displaying altered 
responses when tested for anxiety, aggression and depressive-like 
behaviors. This suggests that changes in the Tph2 activity can affect 
behavior (Lucki, Dalvi et al. 2001; Osipova, Kulikov et al. 2009; Berger, 
Weber et al. 2012). A separate study also demonstrated that the 
different allelic distributions could result in differential reponses to SSRI 
treatment. This supports the role of TPH2 in regulating brain 5-HT 
homeostasis, and also indicates its involvement in resistance to SSRI 
treatment (Cervo, Canetta et al. 2005).  
 
In addition, knock-in mice that express the R439H Tph2 allele 
(R439H Tph2 KI) and Tph2 knockout Tph2-/- mice have also been 
studied. The R439H Tph2 allele is analogous to a rare human R441H 
Tph2 variant, encoded by the SNP G1463A. This SNP has been 
identified in patients with major depression, and causes an 80% 
decrease in Tph2 expression and 5-HT synthesis (Zhang, Gainetdinov 
et al. 2005). R439H Tph2 KI mice display aberrant behaviors, such as 
increased anxiety, aggression, and depressive-like symptoms, further 
supporting the role of Tph2 in modulating behavior (Beaulieu, Zhang et 
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al. 2008). Chronic treatment of R439H Tph2 KI mice with SSRI 
antidepressants, like fluoxetine and paroxetine, also resulted in an 
exacerbation of brain 5-HT deficiency. Nevertheless, this effect can be 
restored by co-treatment with 5-HTP, indicating that Tph2 is involved in 
the proper maintaining of brain 5-HT levels during chronic SSRI 
treatment (Siesser, Sachs et al. 2013).  
 
Unlike R439H Tph2 KI mice, where 5-HT synthesis is reduced, 
Tph2 is ablated in Tph2-/- mice. While Tph2-/- mice can survive into 
adulthood, a lethality rate of 50% is observed within the first four 
weeks. In addition, the absence of brain 5-HT signaling resulted in 
retarded growth, as well as alterations in sleep pattern, 
thermoregulation, cardiovascular functions and breathing. Maternal 
behavior of Tph2-/- mice is also affected, leading to poor care and 
survival of offsprings (Alenina, Kikic et al. 2009). Collectively, studies in 
Tph2 mutant mice have shown that Tph2 plays a role during 
development, as well as in behavioral modulation. In addition, 
disruption of Tph2 is also indicated to give rise to abnormalities in 
behavior, thus implicating its role in neuropsychiatric disorders.  
 
1.2.3 Similarities and differences in properties of the two TPH 
isoforms 
 TPH1 and TPH2 share about 70% identity in their protein 
sequences, with their catalytic and tetramerization domains being  
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FIGURE 1.4. Comparison of amino acid sequences of human 
TPH1 (hTPH1) and human TPH2 (hTPH2). Sequence alignment 
performed using ClustalW revealed that the catalytic and 
tetramerization domains of TPH1 and TPH2 have considerable 
homology. However, their N-terminal regulatory domains are not 
conserved. In particular, the first 58 amino acids are unique to TPH2. 
Furthermore, the first 41 amino acids of TPH2 are not present in the 
TPH1. The regulatory N-terminus of TPH2 comprises of the first 150 
amino acids. Dashed lines denote domain boundaries. Conserved 
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highly homologous (Figure 1.4) (Walther and Bader 2003). 
Furthermore, residues that play crucial roles in the structure and 
function of TPH1 are conserved in TPH2 (Jiang, Yohrling et al. 2000; 
Martinez, Knappskog et al. 2001; McKinney, Teigen et al. 2001; 
Daubner, Moran et al. 2002; Wang, Erlandsen et al. 2002). Both TPH1 
and TPH2 can also be phosphorylated at specific serine residues 
(Jiang, Yohrling et al. 2000; McKinney, Knappskog et al. 2005; Kuhn, 
Sakowski et al. 2007; Winge, McKinney et al. 2008). Despite these 
similarities, characterization studies have revealed numerous 
differences that clearly distinguish the two TPH isoforms. 
 
In addition to the differences in spatial expression (Sakowski, 
Geddes et al. 2006), amino acid sequences within the regulatory 
domains of both TPH isoforms were strikingly divergent. TPH2 has an 
extended regulatory domain as compared to that of TPH1, and the first 
58 amino acids of TPH2 are unique to the isoform, with 41 amino acids 
not present in TPH1 (Figure 1.4) (Walther and Bader 2003). This 
difference in length at the N-terminal is reflected in the protein sizes, 
with each TPH2 subunit (57 kDa) having a slightly higher molecular 
weight as compared to TPH1 (51 kDa). Kinetic characterization on 
enzyme activity in bacteria has also revealed that TPH1 has higher 
Vmax and Km values for BH4 than TPH2, although TPH2 has a higher Km 
value for tryptophan as compared to TPH1. This indicates that TPH2 
has a higher substrate preference and binding affinity to tryptophan, 
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but a lower maximum activity, as compared to TPH1, (McKinney, 
Knappskog et al. 2005). More importantly, physiological studies have 
demonstrated that TPH2 exhibits lower stability as compared to TPH1 
when expressed in mammalian cells, and is also less efficiently 
synthesized (Murphy, Zhang et al. 2008). As the focus of this present 
work is on the regulation of TPH2, TPH1 will only be mentioned as a 
comparison, but not further discussed in the subsequent sections of 
this chapter.  
 
1.2.4 Role of the TPH2 regulatory domain  
Given its distinct amino acid sequence in the regulatory domain, 
the extended N-terminal of TPH2 is the subject of interest in several 
studies as it may confer regulatory mechanisms that are unique to 
TPH2. This in turn can result in the differential properties that 
distinguish TPH2 from TPH1. In vitro studies using mammalian and 
bacterial cells have been carried out to characterize the role of the 
TPH2 N-terminal regulatory domain with respect to its protein 
expression.   
 
The TPH2 protein is generally insoluble and thus difficult to 
purify in its native form (McKinney, Knappskog et al. 2005). However, 
by removing the regulatory domain of human TPH2, enzyme solubility 
was significantly increased. In addition, deletion of the regulatory 
domain also increased TPH2 stability by approximately six-fold 
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(Carkaci-Salli, Flanagan et al. 2006). A separate study carried out in 
mammalian cells reported that protein expression level of TPH2 was 
lower compared to TPH1, even when mRNA levels were not altered. In 
vitro translation and cycloheximide treatment also showed that TPH2 
was synthesized at a slower rate, but underwent degradation faster 
than TPH1. Furthermore, these negative effects on TPH2 expression 
was found to be brought about by the first 58 amino acids of the 
extended N-terminus of TPH2, with residues 11-20 contributing to the 
bulk of the effect (Murphy, Zhang et al. 2008). 
  
As such, the findings suggest that the N-terminal regulatory 
domain can negatively regulate TPH2 activity through reduction of 
protein synthesis and expression, decreasing enzyme solubility and 
destabilization. However, the underlying mechanisms by which the 
TPH2 regulatory domain gives rise to these effects are still unknown. 
 
1.3 REGULATION OF TRYTOPHAN HYDROXYLASE 2 
 Since the discovery of the neuronal specific TPH2, many studies 
have been done to further understand the regulation of the activity and 
expression of this enzyme in the brain. These lines of research not only 
provide new insights to the processes that are involved in brain 5-HT 
synthesis, but also contribute to development of new therapeutic 
strategies that can improve brain 5-HT production as well. It is now 
known that TPH2 expression within the brain can be regulated on both 
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genetic and protein levels, and current knowledge will be discussed in 
this section. However, as this work will focus on TPH2 protein 
regulation in the later chapters, more emphasis will be given to 
regulatory mechanisms at the protein level in this section. 
 
1.3.1 Gene regulation and external factors 
 The regulation of gene expression is the process by which cells 
control the production of gene products, and is usually dependent on 
the untranslated regions of the gene. An early study investigating TPH2 
polymorphisms in rhesus monkeys has suggested that the 3ʼ 
untranslated region (3ʼUTR) can affect the stability of the mRNA 
transcript and translation efficiency (Chen, Novak et al. 2006). 
Characterization of the 5ʼ untranslated region (5ʼUTR) of human TPH2 
has also revealed that the 5ʼUTR exerts an inhibitory effect on TPH2 
gene expression (Chen, Vallender et al. 2008), which may be species 
specific (unpublished data). Furthermore, later studies identified an 
asymmetrical bidirectional promoter and an estrogen response element 
half-site within the 5ʼUTR of TPH2, suggesting that TPH2 expression 
can be regulated by non-coding RNAs as well as estrogen receptor β 
and its agonists (Chen and Miller 2009; Hiroi and Handa 2013). 
Transcription factors, such as POU3F2 (N-Oct-3) and RE-1 silencer of 
transcription (REST/NRSF), have also been revealed to associate with 
the TPH2 5ʼUTR and can regulate TPH2 gene expression by activating 
or repressing transcription, respectively (Patel, Bochar et al. 2007; 
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Scheuch, Lautenschlager et al. 2007). In addition to gene regulation at 
the 5ʼ and 3ʼ UTRs, TPH2 mRNA has been demonstrated to undergo 
alternative splicing and RNA editing, indicating the role of post-
transcriptional regulation in TPH2 expression as well (Grohmann, 
Hammer et al. 2010).  
 
Changes in TPH2 gene expression can be influenced by 
external factors. Several studies have illustrated the fluctuation of 
TPH2 expression according to a circadian rhythm (Liang, Wessel et al. 
2004; Malek, Dardente et al. 2005; Nexon, Sage et al. 2011). 
Furthermore, hormonal levels, estrogen in particular, have been shown 
to regulate TPH2 mRNA transcript levels (Hiroi, McDevitt et al. 2006; 
Donner and Handa 2009; Bethea, Smith et al. 2011; Charoenphandhu, 
Teerapornpuntakit et al. 2011; Hiroi and Handa 2013). Interestingly, 
diet has also been implicated in TPH2 mRNA expression (McNamara, 
Able et al. 2009; Hageman, Wagener et al. 2010; Sullivan, Grayson et 
al. 2010). Finally, there have been increasing evidence indicating that 
TPH2 gene expression can be regulated by stress and glucocorticoids 
(Brown, Henderson et al. 2006; Malek, Sage et al. 2007; McEuen, Beck 
et al. 2008; Gardner, Hale et al. 2009; Heydendael and Jacobson 
2009; Chen and Miller 2012; Donner, Montoya et al. 2012). 
Nevertheless, with the exception of estrogen regulation, molecular 
mechanisms underlying the crosstalk between the environmental 
triggers and TPH2 gene expression have not been fully elucidated. 
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1.3.2 Post-translational modifications 
Post-translational modifications occur after proteins are 
synthesized, and act to control the functions and alter the structures of 
the proteins through the attachment of biochemical functional groups. 
Characterization studies on TPH1 have suggested that post-
translational phosphorylation by protein kinases are involved in their 
regulation and thermal stability (Jiang, Yohrling et al. 2000). As TPH2 
share 70% homology with TPH1, it is likely that TPH2 can also be 
modulated by phosphorylation. Incidentally, even before the 
identification of TPH2, TPH isolated from the brain stem has already 
been demonstrated to be phosphorylated and activated by protein 
kinases, namely protein kinase A (PKA) and calcium, calmodulin-
dependent kinase II (CaMKII) (Ehret, Cash et al. 1989; Johansen, 
Jennings et al. 1996). These early observations were further confirmed 
in later studies, after TPH2 was recognized as a neuronal specific TPH 
isoform.  
 
Using mass spectrometry analyses, separate studies have 
shown that phosphorylation of TPH2 can occur on serine residue 19 
(S19). This modification can be mediated by both PKA as well as 
CaMKII, which in turn can increase the catalytic activity of the enzyme 
two fold (McKinney, Knappskog et al. 2005; Kuhn, Sakowski et al. 
2007). Another study has also demonstrated that the induction of PKA 
by forskolin can result in the phosphorylation of S19 in wild type mouse 
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TPH2, as well as bring about an increase in protein expression and 5-
HT synthesis. Using site-directed mutagenesis, the study also showed 
that the increase in TPH2 expression and activity was reduced in a 
S19A mutant, whereas a pseudophosphorylated S19D mutant of TPH2 
exhibited a 2.5 fold increase in protein and 5-HT production (Murphy, 
Zhang et al. 2008). In addition to S19, both PKA and CaMKII have 
been shown to phosphorylate serine residue S104, which also leads to 
increased TPH2 activity and stability. Furthermore, phosphorylation at 
either S19 or S104 was found to increase the rate of phosphorylation 
on other phosphorylation sites in the enzyme, indicating that different 
kinase pathways may regulate TPH2 synergistically (Winge, McKinney 
et al. 2008). Taken together, these findings supported the earlier 
observations and further established that TPH2 protein expression and 
activity can be regulated by phosphorylation. 
 
 In addition to the role of phosphorylation in TPH2 regulation, 
findings from recent studies have suggested that other post-
translational modifications may also occur on TPH2. Firstly, lysine 
residue 79 (K79) has been identified as a potential acetylation site, as 
detected by tandem liquid chromatography tandem mass spectrometry 
(LC/LC-MS/MS) in total liver protein lysates (Zhao, Xu et al. 2010). 
However, the detection of TPH2 in liver tissues is unexpected, and 
there have yet to be any reports validating the acetylation on K79. 
Nevertheless, protein acetylation can play a role in enzyme activation 
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or inhibition, as well as regulating protein stability (Zhao, Xu et al. 
2010). As such, it would be interesting to determine whether K79 can 
indeed be acetylated, and how acetylation may affect the regulation of 
TPH2 expression and activity. Secondly, a separate study has 
demonstrated that all thirteen cysteine residues on TPH2 are able to 
undergo disulphide cross-linking in the presence of oxidative stressors. 
As this modification does not exhibit residue specificity, any cysteine 
residue on TPH2 can be involved in the cross-linking reaction. 
Functionally, disulphide cross-linking was found to cause the formation 
of TPH2 aggregates in vitro, resulting in inhibition of TPH2 activity 
(Kuhn, Sykes et al. 2011). Collectively, studies have demonstrated that 
phosphorylation, formation of disulphide linkages and possibly 
acetylation can occur on TPH2. Nevertheless, it is still uncertain 
whether TPH2 can be modified by other post-translational 
modifications.   
 
1.3.3 Protein-protein interactions  
In addition to biochemical modifications, interactions with other 
protein partners can also play a role in regulating protein function and 
activity. This is evident in most essential cellular processes, such as 
DNA replication, translation and signaling transduction. As such, 
identifying protein-protein interactions involving TPH2 can contribute to 
a better understanding of its regulatory network, which in turn may 
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allow us to uncover novel targets in the treatment of conditions 
involving dysregulation of the brain serotonergic system.   
 
To date, 14-3-3 proteins are the only known interacting partners 
of TPH2. Prior to the recognition of TPH2 as a separate isoform from 
TPH1, TPH isolated from rabbit brain has already been demonstrated 
to bind to 14-3-3 proteins, under conditions where TPH was 
phosphorylated. Complex formation between phosphorylated TPH and 
14-3-3 proteins is also shown to activate TPH and increase enzyme 
activity, and at the same time prevent TPH dephosphorylation (Banik, 
Wang et al. 1997). A later study further supported these observations 
by showing that PKA phosphorylation of human TPH2 can result in 
high affinity binding to some 14-3-3 proteins, such as 14-3-3γ, 14-3-3ε 
and BMH1. This interaction with 14-3-3 proteins further increases the 
catalytic activity and stability of TPH2 (Winge, McKinney et al. 2008). 
Nevertheless, the site of interaction between TPH2 and the 14-3-3 
proteins, as well as the mechanisms by which 14-3-3 proteins stabilize 
TPH2, have not been fully elucidated. 
 
1.4 IMPLICATIONS OF TPH2 IN PSYCHIATRIC DISORDERS 
 With the recognition of TPH2 as the neuronal specific, rate-
limiting enzyme in the synthesis of brain 5-HT, many association and 
polymorphism studies, on both genetic and protein levels, have 
implicated TPH2 in a wide range of neuropsychiatric disorders, where 
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regulation of the serotonergic system is disrupted. Although by no 
means exhaustive, some association studies focusing on single 
nucleotide polymorphisms (SNP) in humans will be highlighted in this 
section, illustrating the role of TPH2 dysregulation in neuropsychiatric 
conditions. 
 
1.4.1 Affective disorders 
 Affective disorders are a group of disorders in which mood is 
affected, and are made up of several psychiatric conditions. Major 
depressive disorder, or unipolar depression, and bipolar disorders are 
the most common. As affective disorders are complex disorders, it is 
possible that a single SNP can give rise to several conditions (Lesch 
2004).  
 
1.4.1.1 Major depressive disorder  
 Major depression is a disabling condition whereby mood, sleep, 
appetite, cognition and psychomotor activity may be affected (Fava and 
Kendler 2000). Many studies have already associated different SNPs 
within the TPH2 gene to major depression (Zill, Baghai et al. 2004; 
Zhang, Gainetdinov et al. 2005; Zhou, Roy et al. 2005; Van Den 
Bogaert, Sleegers et al. 2006; Tsai, Hong et al. 2009; Gao, Pan et al. 
2012). Although most SNPs are located in introns and untranslated 
regions, two rare SNPs within the TPH2 coding region have been 
detected. Notably, the SNP G1463A encodes a missense mutation 
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(R441H) in the TPH2 protein, resulting in a significant decrease in 5-HT 
synthesis (Zhang, Gainetdinov et al. 2005). However, the rarity of this 
functional polymorphism has resulted in varying reports of its presence 
by various groups (Garriock, Allen et al. 2005; Zhou, Roy et al. 2005). 
In addition, the SNP rs17110563 causes a P206S substitution in TPH2, 
resulting in reduced enzyme stability and solubility (Zhou, Roy et al. 
2005; Cichon, Winge et al. 2008). Taken together, detection of SNPs 
within the TPH2 gene in depressed patients suggests that TPH2 is 
associated with major depression.     
 
1.4.1.2 Bipolar disorder 
 Bipolar affective disorder is a mental condition whereby patients 
can experience recurrent fluctuations of elevated mood and depression 
(Anderson, Haddad et al. 2012). Genetic studies on TPH2 have 
detected several SNPs that are associated with bipolar disorder 
(Harvey, Shink et al. 2004; Van Den Bogaert, Sleegers et al. 2006; 
Harvey, Gagne et al. 2007; Lin, Chao et al. 2007; Lopez, Detera-
Wadleigh et al. 2007; Cichon, Winge et al. 2008; Roche and McKeon 
2009; Campos, Miranda et al. 2011). Furthermore, the SNP C2755A 
can encode for a S41Y substitution in the regulatory domain of the 
TPH2 protein, affecting enzyme phosphorylation and resulting in 
reduced enzyme stability and activity (Carkaci-Salli, Salli et al. 2014). 
Interestingly, comorbidity with other conditions like major depression, 
suicidal behaviors and panic disorder was detected with some SNPs in 
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the TPH2 gene, indicating the complex nature of the behavioral effects 
that can be controlled by TPH2 expression (Van Den Bogaert, Sleegers 
et al. 2006; Lin, Chao et al. 2007; Lopez, Detera-Wadleigh et al. 2007; 
Campos, Miranda et al. 2011).  
 
1.4.1.3 Suicidal behavior 
 Suicidal behavior can be manifested as part of the behavioral 
spectrum in affective disorders, particularly in major depression and 
bipolar disorder. Nevertheless, comorbidity with other psychiatric 
disorders is common (Hawton and van Heeringen). SNP and haplotype 
analyses of the TPH2 gene in suicide victims and patients with suicide 
attempts have also revealed an association of TPH2 with suicidal 
behavior (Zill, Buttner et al. 2004; Ke, Qi et al. 2006; Jollant, Buresi et 
al. 2007; Lopez de Lara, Brezo et al. 2007; Lopez, Detera-Wadleigh et 
al. 2007; Yoon and Kim 2009). Furthermore, increase in TPH2 mRNA 
transcript levels was observed in dorsal raphe of suicide victims (Bach-
Mizrachi, Underwood et al. 2006). Taken together, these findings 
suggest that changes in TPH2 levels within the brain may influence the 
decisions and behaviors leading to suicide. 
 
1.4.1.4 Attention-deficit hyperactivity disorder 
 Attention-deficit hyperactivity disorder (ADHD) is a common 
neuropsychiatric condition diagnosed in children and adolescents, and 
is typically characterized by short attention spans, hyperactivity or 
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restlessness, and impulsive and disruptive behaviors (Polanczyk, de 
Lima et al. 2007). Since the identification of TPH2, several studies have 
associated polymorphisms of this neuronal specific TPH to ADHD 
(Sheehan, Lowe et al. 2005; Walitza, Renner et al. 2005; Brookes, Xu 
et al. 2006; Lasky-Su, Neale et al. 2008; Manor, Laiba et al. 2008; 
Park, Park et al. 2013), indicating that TPH2 can influence the changes 
in cognitive processes and motor activity underlying the behaviors 
observed in ADHD patients. In addition, a functional TPH2 SNP C907T 
has also been identified to be associated with ADHD. This SNP 
encodes a missense R303W mutation in TPH2, resulting in decreased 




 Schizophrenia is a psychiatric disorder where patients can both 
exhibit negative symptoms such as abnormal social behavior, inactivity 
and lack of motivation, as well as positive symptoms like delusions, 
confusion in thinking and hallucinations. As dysregulation of serotonin 
signaling has been related to schizophrenia, genetic studies have been 
performed to determine whether TPH2 has a direct role in the 
pathophysiology of schizophrenia. To date, genetic association 
between TPH2 and schizophrenia is still relatively inconclusive.  
Several studies have shown that SNPs in the TPH2 gene are 
associated with schizophrenia or its positive symptoms (Zhang, Li et al. 
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2011; Schuhmacher, Becker et al. 2012; Xu, Ding et al. 2014). On the 
other hand, a number of reports did not find associations between 
TPH2 SNPs and schizophrenia (Shiroiwa, Hishimoto et al. 2010; Tee, 
Chow et al. 2010; Kim and Yoon 2011; Watanabe, Egawa et al. 2012). 
Nevertheless, these conflicting findings may be due to the 
heterogeneous nature of schizophrenia and the population analyzed. 
Moreover, differences in methodologies and sample sizes may also 
contribute to the discrepancy.  
 
1.4.3 Panic disorder 
 Panic disorder is another complex neuropsychiatric condition 
that is manifested through anxiety attacks. In addition to affective 
disorders and schizophrenia, associations of TPH2 SNPs with panic 
disorders have been detected (Maron, Toru et al. 2008; Kim, Lee et al. 
2009). While contradictory findings have also been reported (Mossner, 
Freitag et al. 2006), the heterogeneous nature of neuropsychiatric 
disorders and the role of TPH2 in these conditions are further 
reiterated. 
 
1.4.4 Autism  
 Autism is a neurodevelopmental disorder that, like ADHD, is a 
condition more commonly diagnosed in children. Autistic patients 
typically exhibit impaired social behaviors as well as repetitive 
behavior, which can be influenced by 5-HT. As TPH2 controls brain 5-
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HT synthesis, genetic studies on TPH2 have also been carried out to 
determine whether TPH2 is associated with autism. Several 
association studies have suggested that TPH2 polymorphisms are 
related to autism (Coon, Dunn et al. 2005; Yang, Yoo et al. 2012; 
Egawa, Watanabe et al. 2013; Singh, Chandra et al. 2013). 
Nevertheless, conflicting results have also been reported (Sacco, 
Papaleo et al. 2007). This could be due to differences in methodology 
and the populations sampled, compounded by the complex nature of 
the disorder.   
 
1.5 OBJECTIVES OF STUDY AND HYPOTHESES 
Current treatment of neuropsychiatric disorders that involve the 
brain serotonergic system includes drugs like selective serotonin 
reuptake transporters (SSRIs) and monoamine oxidase inhibitors 
(MAOIs) (Veenstra-VanderWeele, Anderson et al. 2000). This 
effectively increases 5-HT signaling by preventing 5-HT reuptake or 
breakdown, respectively. 5-HT receptor agonists and antagonists, such 
as atypical antipsychotics, can also alter downstream signaling 
pathways by modulating the effects of 5-HT. However, these 
treatments often result in undesirable side effects in patients, such as 
nausea, insomnia and even sexual dysfunction, possibly due to their 
action on the peripheral system (Stahl 1998; Yamada and Yasuhara 
2004). With the discovery of TPH2 and its implications in these 
psychiatric disorders, this neuronal-specific isoform of TPH may play a 
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more specific role in the regulation of 5-HT levels in the brain. As TPH2 
presents an attractive target for the development of improved 
therapeutic interventions with fewer side effects, it is important to 
elucidate regulatory mechanisms of this rate-limiting enzyme. This in 
turn would allow the development of more effective treatments and 
diagnosis of psychiatric disorders in the near future. 
 
As such, the focus of this work is to study the regulatory 
pathways that are involved in regulating TPH2 protein expression and 
activity. Specifically, we aim to identify novel regulators of TPH2 that 
may affect its stability, as well as elucidate mechanisms that can give 
rise to the instability of TPH2 in vitro. Since protein-protein interaction 
analyses of TPH2 using the whole human proteome has yet to be 
performed, we postulated that additional TPH2 interacting partners 
may exist, in addition to 14-3-3 proteins. We also speculated that 
differences in amino acid sequences of the TPH1 and TPH2 regulatory 
domains could result in differential interaction with binding partners. In 
addition, previous in vitro studies have also established the instability 
and rapid degradation of TPH2, although the degradation pathway was 
yet to be determined. We postulated that TPH2 could undergo 
degradation through the ubiquitin proteasome pathway, since TPH1 
has been reported to undergo ubiquitination (Kojima, Oguro et al. 
2000). Moreover, we hypothesized that both TPH isoforms could be 
ubiquitinated to different extents, possibly as a result of their differential 
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regulatory domains, thus giving rise to their differences in stability in 
vitro. These hypotheses will be further investigated in chapters 2 and 3. 
We believe the findings in this present study will provide new insights 
into the mechanisms underlying TPH2 stability, which in turn can 
contribute to the development of novel therapeutic approaches that can 
improve the stability of TPH2, and ultimately increase brain 5-HT 
synthesis.  
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2. THE REGULATION OF TRYPTOPHAN HYDROXYLASE-2 BY 
HEAT SHOCK PROTEIN HSP70 
 
2.1 INTRODUCTION 
Serotonin (5-hydroxytryptamine or 5-HT) is a major monoamine 
neurotransmitter that is synthesized from L-tryptophan in a two-step 
enzyme reaction. The first and rate-limiting step of this reaction is 
catalyzed by tryptophan hydroxylases (TPH), which are expressed in 
serotonergic neurons in the central nervous system as well as in 
peripheral tissues such as intestinal enterochromaffin cells, 
thrombocytes and mast cells of connective tissues (Veenstra-
VanderWeele, Anderson et al. 2000; Walther and Bader 2003; Walther, 
Peter et al. 2003). Two isoforms of TPH have been identified, and are 
encoded by two independent genes (Walther and Bader 2003). TPH1 
is predominantly expressed and controls 5-HT synthesis in the 
periphery, while TPH2 is neuronal-specific and regulates 5-HT 
synthesis in the brain (Zhang, Beaulieu et al. 2004). Previous efforts 
made to characterize both isoforms have revealed that while TPH1 and 
TPH2 have highly similar catalytic and tetramerization domains, their 
N-terminal regulatory domains are divergent. In particular, the first 41 
amino acids of TPH2 are unique to the isoform (Walther and Bader 
2003). It has been suggested that the dissimilarity in their regulatory 
domains can give rise to differences in enzymatic properties and 
regulation of protein stability. Indeed, TPH2 has lower protein 
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expression levels and undergoes degradation at a faster rate 
compared to TPH1 (Murphy, Zhang et al. 2008). In addition, the 
instability and lower solubility of TPH2, when purified in vitro, were 
attributed to the first 150 amino acids that form the TPH2 N-terminal 
regulatory domain (McKinney, Knappskog et al. 2004; McKinney, 
Knappskog et al. 2005; Carkaci-Salli, Flanagan et al. 2006). 
 
Similar to other amino acid hydroxylases, the regulatory 
domains of TPH1 and TPH2 act to control enzyme expression, activity 
and stability, and thus are involved in regulating 5-HT synthesis 
(Fitzpatrick 1999). Earlier studies on the regulatory mechanisms of 
TPH2 have demonstrated that post-translational phosphorylation of 
specific amino acid residues in the regulatory domain of TPH2 can 
stabilize its expression and activity (McKinney, Knappskog et al. 2005; 
Murphy, Zhang et al. 2008). The phosphorylation of TPH2 was also 
shown to allow interaction with 14-3-3 proteins, which in turn increases 
enzyme stability (Winge, McKinney et al. 2008). While the role of 
phosphorylation and protein-protein interactions in the regulation of 
TPH2 expression and stability are beginning to be understood, 
additional modifications and protein regulators may exist, but have yet 
to be elucidated. 
 
Heat shock protein 70 (HSP70) is a family of highly conserved 
70 kDa molecular chaperones, which includes the stress inducible 
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HSP70 (HSP70-1, HSPA1A) and constitutively expressed heat shock 
cognate 70 (HSC70, HSPA8). When induced as part of the stress 
response, HSP70 proteins are able to prevent the aggregation and 
degradation of proteins, in turn improving protein stability during stress 
(Mayer and Bukau 2005). In addition, HSP70 proteins can aid the 
folding and subcellular transport of newly synthesized proteins, and 
also play a role in protein degradation under non-stress conditions 
(Chiang, Terlecky et al. 1989; Bercovich, Stancovski et al. 1997; 
Frydman 2001; Pratt and Toft 2003). Consistent with its role in protein 
homeostasis, HSP70 proteins have been implicated in various 
diseases, including neurodegeneration, immunomodulation and cancer 
(Turturici, Sconzo et al. 2011). 
 
In this study, we found a novel TPH-interacting protein, 
interacting with both TPH1 and TPH2 in vitro. Using mass 
spectrometry, we have identified this protein to be HSP70 (HSP70-1, 
HSPA1A). A stronger interaction was observed between HSP70 and 
TPH1, while interaction was weaker between HSP70 and TPH2. Our 
results also suggested that the main HSP70 interaction domains on 
both TPH isoforms could be located within the N-terminal regulatory 
domains. Pharmacological inhibition demonstrated that TPH2 was 
more sensitive to changes in levels of HSP70, as compared to TPH1. 
Furthermore, RNA interference indicated that HSP70 functions as a 
positive regulator of TPH2 enzyme expression and activity, possibly by 
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stabilizing protein folding. Taken together, our results indicated that the 
instability of TPH2 was in part due to its poor interaction with HSP70. 
 
2.2 EXPERIMENTAL PROCEDURES 
2.2.1 Cell culture and reagents  
PC12 cells were maintained in Dulbeccoʼs modified Eagleʼs 
medium, supplemented with 10% horse serum (Gibco, Life 
Technologies) and 5% bovine calf serum (HyClone, Thermo Scientific). 
HEK293 cells were maintained in Eagleʼs minimal essential medium 
with Earleʼs salt, supplemented with 10% fetal bovine serum (HyClone, 
Thermo Scientific) and 0.1% gentamicin solution (Life Technologies). 
N-Formyl-3,4-methylenedioxy-benzylidine-γ-butyrolactam (KNK437, 
Calbiochem) was prepared as a 50 mM stock solution in dimethyl 
sulfoxide. Dimethyl sulfoxide was used as a control in treatment 
assays. Doxycycline (Clontech, Takara) was prepared in water as a 1 
mg/ml stock solution. 
 
2.2.2 Molecular reagents and transfection  
HEK293 cells were transiently transfected using calcium 
phosphate method. Transient transfection in PC12 cells was performed 
using Lipofectamine 2000 transfection reagent (Life Technologies) 
according to manufacturerʼs instructions; or by electroporation, using a 
Gene Pulser II (Bio-Rad), at 300 V and 1000 μF. All overexpression 
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constructs were generated with a triple hemagglutinin (HA) tag at the N 
terminus and inserted into pcDNA3.1 vector (Invitrogen), as previously 
described (Murphy, Zhang et al. 2008). The doxycycline inducible HA-
tagged TPH2 was sub-cloned into pTRE-Tight vector (Clontech) at 
EcoRV and XbaI sites, and transfected into PC12 cells stably 
expressing pTet-On vector (Clontech), which contained the reverse 
tetracycline controlled transactivator (rtTA) gene. shRNA inserts were 
designed using BLOCK-iT™ RNAi Designer (Invitrogen). Full-length 
shRNA inserts were generated by short oligomer annealing and T4 
polynucleotide kinase (New England BioLabs) treatment, and then 
cloned into pBluescript SK+ (Stratagene) containing a H1 promoter, at 
BglII and HindIII sites. All generated constructs were confirmed by 
sequencing. 
 
2.2.3 Immunoprecipitation and SDS-PAGE  
HEK293 cells were collected 48 h post-transfection, and then 
resuspended in lysis buffer (20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 
mM EGTA, 1% Triton-X100) in the presence of 5 mM 
phenylmethylsulfonyl fluoride (Sigma-Aldrich) and 1x Complete EDTA-
free protease inhibitor (Roche), using a pellet homogenizer (Kontes, 
Fisher Scientific). Lysates were centrifuged at 13200 rpm for 10 min at 
4°C, and resulting supernatants were incubated with anti-HA agarose 
(Sigma-Aldrich) or sepharose A/G beads (Pierce, Thermo Scientific) 
conjugated to anti-HSP70 antibodies (Stressgen, Enzo Life Sciences) 
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overnight, on a rotator at 4°C. Beads were washed thoroughly with 
lysis buffer, and bound proteins were eluted using 1x Laemmli buffer 
with 10% β-mercaptoethanol. For mass spectrometry, elution of bound 
proteins was performed using 1 M glycine to reduce the presence of 
IgG heavy and light chains that may hinder analyses. All eluted 
proteins were heated at 55°C for 20 min before separation by SDS-
PAGE. Immunoprecipitated samples for mass spectrometry analyses 
were resolved on 10% Ready Gel Tris-HCl precast gels (Bio-Rad) and 
stained with InstantBlue (Expedeon) according to the manufacturerʼs 
instructions. Eluted samples for Western blotting were resolved and 
immunoblotted as described below. 
 
2.2.4 Western blotting  
At 48-72 h post-transfection, or the indicated time points after 
pharmacological treatment, cells were collected and resuspended in 
RIPA buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-
40, 1% sodium deoxycholate, 0.1% SDS) with 5 mM 
phenylmethylsulfonyl fluoride (Sigma-Aldrich) and 1x Complete EDTA-
free protease inhibitor (Roche) for lysis. Soluble proteins were 
separated by centrifugation at 13200 rpm for 10 min at 4°C, and 
quantified using DC protein assay kit (Bio-Rad). Protein samples were 
then diluted in 2x Laemmli sample buffer with 10% β-mercaptoethanol 
and incubated at 55°C for 15 min before electrophoresis. Protein 
samples were loaded in equal amounts, unless otherwise stated, and 
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resolved on 10% SDS-PAGE before being transferred onto 
nitrocellulose membranes (Bio-Rad). Antibodies used for detection of 
proteins of interest were as follows: anti-HA (Covance Inc.), anti-actin 
(Millipore), anti-HSP70 (SPA-810, Stressgen, Enzo Life Sciences), and 
anti-HA Peroxidase (Roche). All primary antibodies were incubated 
overnight at 4°C. Immunoblots probed with non-peroxidase conjugated 
antibodies were incubated with horseradish peroxidase conjugated 
goat anti-mouse secondary antibodies (Pierce, Thermo Scientific). All 
blots were then developed using SuperSignal West Pico 
Chemiluminescent Substrate kit (Pierce, Thermo Scientific), and 
detected with Fujifilm Super RX-N film or visualized using ImageQuant 
LAS 4000 Biomolecular Imager (GE Healthcare). For quantification of 
protein levels, band intensities from at least three independent 
experiments were quantified using ImageJ software (Version 1.43u, 
National Institutes of Health). 
 
2.2.5 Measurement of 5-HT levels 
PC12 cells stably expressing the rtTA transactivator protein from 
the pTet-On vector (Clontech) were treated with doxycycline for 18 h, 
and then counted using a hemocytometer. The cells were washed 
using phosphate-buffered saline, and resuspended in 0.5 N perchloric 
acid using a pellet homogenizer (Kontes, Fisher Scientific). The 
homogenates were separated by centrifugation at 13200 rpm for 5 min 
at 4°C, and supernatants were filtered using 0.2 μm centrifugal filter 
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units (Millipore). Filtrates were then analyzed by high pressure liquid 
chromatography (HPLC) with electrochemical detection. Samples were 
separated on an ESA microdialysis MD-150 analytical column (3 mm x 
15 cm; Thermo Scientific Dionex), with a mobile phase of 90 mM 
sodium phosphate monobasic dihydrate, 50 mM citric acid, 2.1 mM 1-
octanesulfonate monohydrate, 0.1 mM EDTA, and 12.5% acetonitrile at 
pH 3.0. Electrode potential was applied at +200 mV. 5-HT levels were 
recorded and quantified within a linear range based on a series of 5-HT 
standards of known concentrations, then normalized to the cell number 
within each analyzed sample. 
 
2.2.6 Mass spectrometry  
One-step peptide extraction and MALDI-TOF/TOF MS analyses 
was performed by The Proteomic Core Facility of the Biological 
Research Center at Nanyang Technological University, as described 
previously (Meng, Zhang et al. 2008). Briefly, bands of interest were 
excised and subjected to in-gel digestion with trypsin. Trypsin digestion 
was then inactivated, and conditioned C18 Empore Disks (3M) were 
incubated in the digested solution before bound peptides were eluted. 
Subsequently, MS analyses were carried out using a MALDI-TOF/TOF 
mass spectrometer (Applied Biosystems). MS and MS/MS data were 
acquired in combination mode, and the combined MS and MS/MS 
spectra was processed using GPS Explorer 3.6 (Applied Biosystems) 
and searched against the Swiss-Prot database using MASCOT 2.0 
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server. The searches were carried out at a precursor ion tolerance of < 
0.15 Da and MS/MS fragment ion error tolerance of < 0.3 Da. Oxidized 
methionine was included as a variable modification, while 
carbamidomethyl cysteine was selected as a fixed modification. 
Proteins with significance scores of p < 0.05 were considered as true 
positives. 
 
2.2.7 Statistical analyses and bioinformatics 
Protein sequence alignment was performed using ClustalW2 
(EMBL-EBI). Studentʼs two-tailed t test was used to compare the 
differences in HSP70 interaction between TPH1 and TPH1 Δ10 
truncated mutant, as well as differences in expression between TPH1 
and TPH2 after pharmacological treatment or RNA interference. All 
other differences in HSP70 interaction were compared using analysis 
of variance with Tukeyʼs post hoc analysis. Data was considered to be 
statistically significant when p < 0.05.  Statistical analyses were 
performed and all graphs were plotted using GraphPad Prism (Version 
5.0d, GraphPad Software).  
 
2.3 RESULTS 
2.3.1 HSP70 interacts with both isoforms of TPH 
In order to identify interacting partners of TPH, HA-tagged TPH1 
and TPH2 were transiently expressed in HEK293 cells. 
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Immunocomplexes were pulled down using anti-HA agarose, and 
immunoprecipitated fractions were then resolved on SDS-PAGE. We 
have observed that, in addition to the bait HA-tagged TPH isoforms, 
higher molecular weight proteins were also detected in the 
immunoprecipitated fractions (Figure 2.1A). These proteins were of 
similar sizes, and co-immunoprecipitated together with HA-TPH1 and 
HA-TPH2, but not with HA-YFP, indicating that the interaction was 
specific to both TPH isoforms. MALDI-TOF/TOF MS was used to 
determine the identity of these higher molecular weight proteins. From 
two independent experiments, we identified them to be members of the 
70 kDa heat shock protein family. Proteins with the highest scores 
include HSP70, HSP70Bʼ, HSC70 and HSPA1L (Figure 2.1B, Table 
2.1). As HSP70 is a common interacting protein of both TPH1 and 
TPH2, we further investigated its interaction and role with respect to the 
regulation of TPH expression and stability. Immunoprecipitation using 
anti-HA antibodies and Western blot confirmed that exogenous HA-
TPH1 and HA-TPH2 could interact with endogenous HSP70 (Figure 
2.1, C and D). To determine whether HSP70 interaction could also 
occur in the absence of transient overexpression, we generated 
HEK293 cells lines that stably express HA-TPH1 and HA-TPH2. 
Endogenous HSP70 was observed to co-immunoprecipitate with HA-
TPH1 and HA-TPH2 in these stable HEK293 cells, when pulled down 
using anti-HSP70 antibodies and detected by Western blot (Figure 2.1, 
E and F). As little or no protein-protein interactions were observed  
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FIGURE 2.1. HSP70 is a novel interacting protein of both TPH 
isoforms. A, HA-TPH1 and HA-TPH2 were transiently overexpressed 
in HEK293 cells and immunoprecipitated (IP) to identify interacting 
proteins. Bands of interest (arrows) were detected using Coomassie 
Blue and excised from SDS-PAGE, then analyzed by MALDI-TOF. B, A 
representative MS/MS spectrum of a tryptic peptide fragment from 
HSP70. C, Interactions between endogenous HSP70 with TPH1 and 
TPH2 were confirmed using immunoblotting, using HA-TH and HA-YFP 
as negative controls. 20 μl of HA-TPH1 and HA-TPH2 lysate input 
fractions, and 2 μl of HA-TH and HA-YFP lysate input fractions were 
loaded on SDS-PAGE for Western blot. D, Densitometry analysis was 
performed on immunoblots similar to that in C. Band intensities of 
HSP70 were normalized to that of the HA-tagged substrates in the IP 
fractions, and presented as a ratio to HSP70 interaction with HA-TPH1. 
HA-YFP was not represented in the graph as its interaction with HSP70 
was not observed. E, Reciprocal IP using HSP70 antibodies revealed 
interactions between HSP70 with HA-TPH1 and HA-TPH2 in HEK293 
stable cells. F, Quantification of the extents of HSP70 interaction with 
HA-TPH1 or HA-TPH2 in HEK293 stable cells. Band intensities of HA-
tagged substrates were normalized to that of HSP70 in the IP fractions, 
and presented as a ratio to HSP70 interaction with HA-TPH1; p = 
0.0535 when HSP70 interaction with HA-TPH2 was compared to that of 
HA-TPH1. All graphical data are means ± S.E. (n=3). 
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TABLE 2.1. Higher molecular weight interacting partners of TPH1 
and TPH2 








TPH1 interacting proteins 
Heat shock 70 kDa protein 1 
(HSPA1A, HSP70) 
 
70280.1 P08107 264 100.000 
Heat shock 70 kDa protein 6 
(HSPA6, HSP70B') 
 
71440.4 P17066 123 100.000 
Heat shock cognate 71 kDa 
protein (HSPA8, HSC70) 
 
71082.3 P11142 98 100.000 
Heat shock 70 kDa protein 1L 
(HSPA1L) 
 
70730.5 P34931 60 98.359 
TPH2 interacting proteins 
Heat shock 70 kDa protein 1 
(HSPA1A, HSP70) 
 
70280.1 P08107 118 100.000 
 
Proteins within excised bands (arrows, from Figure 2.1A) were 
identified by MALDI-TOF/TOF MS. Alternative names of the proteins 
were provided within parentheses. Accession numbers were given in 
UniProtKB/Swiss-Prot format. Only the hits with protein scores above 
55 were considered significant (p < 0.05) and represented in the table. 
Confidence levels of the protein scores were reflected as confidence 
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when HA-tagged tyrosine hydroxylase (HA-TH) or HA-YFP were 
expressed (Figure 2.1, C and D), these results indicated that 
interactions between HSP70 with TPH1 and TPH2 were specific. 
 
2.3.2 HSP70 interacts with TPH1 primarily through the N-terminal 
regulatory domain 
As TPH1 was found to be a stronger interacting partner with 
HSP70, we sought to determine the HSP70 interaction domain of 
TPH1. Comparison of the amino acid sequences of TPH1 and TPH2 
revealed that the N-terminal regulatory domains of the two isoforms 
were not conserved (Walther and Bader 2003) (Figure 2.2A). 
Furthermore, the differences in the regulatory domains of TPH1 and 
TPH2 have been shown to give rise to differences in enzyme stability 
and expression (Murphy, Zhang et al. 2008). As such, we hypothesized 
that differences in the regulatory domain sequences could result in 
different extents of interaction with HSP70.  
 
In order to investigate this hypothesis, we have to first determine 
the interaction site of HSP70. As such, we generated a series of HA-
tagged N-terminal deletion mutants of TPH1 (Figure 2.2B). 
Immunoprecipitation and Western blot demonstrated that when the first 
ten amino acids in the N-terminal regulatory domain of TPH1 were 
removed, enzyme expression and interaction with endogenous HSP70 
decreased significantly (Figure 2.2, C and D). Subsequent progressive 
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N-terminal truncations of TPH1 resulted in a more gradual decrease in 
enzyme expression and HSP70 interaction (data not shown). As such, 
our results indicated that the first ten amino acids of TPH1 could play a 
role in HSP70 interaction, and in turn affect enzyme expression and 
stability. 
 
To further investigate the role of the first ten amino acids of 
TPH1 (hereby termed as T1) in HSP70 interaction and enzyme 
stability, chimeric mutants were made (Figure 2.3A). As T1 is not 
conserved between the two isoforms of TPH, a HA-tagged substitution 
mutant, HA-TPH2-T1S, was generated. In this mutant construct, amino 
acids 2-10 of TPH1 replaced their corresponding amino acid sequence, 
amino acids 43-51, on TPH2 (Figure 2.2A and 2.3A). In addition, we 
also noted that the potential HSP70 interaction site in TPH2 was not 
found at the N-terminus like that of TPH1. As such, the first 41 amino 
acids unique to TPH2 might interfere with the interaction between 
HSP70 and amino acids 43-51 of TPH2. To address this possibility, we 
generated a HA-tagged insertion mutant, HA-TPH2-T1E, where amino 
acids 2-10 of TPH1 were added to the N-terminus of TPH2 (Figure 
2.3A). Immunoprecipitation and Western blot were performed using 
these chimeric mutants to determine expression levels and HSP70 
interaction. We observed an increase in protein expression in both 
chimeric mutants as compared to wild type HA-TPH2, with HA-TPH2-  
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FIGURE 2.2. Mapping the interaction domain of HSP70 in TPH1. A, 
The N-terminus of TPH1 and TPH2 are divergent, although amino 
acids 41-51 of TPH2 show some similarity with amino acids 2-10 of 
TPH1. B, TPH1 N-terminal deletion constructs were made in order to 
determine the region of interaction with HSP70. C, IP of HEK293 cell 
lysate overexpressing the TPH1 Δ10 truncated mutant (HA-Δ10-TPH1) 
indicated that interaction of TPH1 with endogenous HSP70 decreased 
significantly when the first 10 amino acids of TPH1 were removed. D, 
Quantification of the extents of HSP70 interaction with HA-TPH1 or HA-
Δ10-TPH1. Band intensities of HSP70 were normalized to that of the 
HA-tagged substrates in the IP fractions, and presented as a ratio to 
HSP70 interaction with HA-TPH1; **, p < 0.05 compared to HSP70 
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FIGURE 2.3. HSP70 interacts with first 10 amino acids in N-
terminus of TPH1. A, Insertion and substitution mutants (HA-TPH2-
T1E and HA-TPH2-T1S) were constructed to further investigate the 
role of the first 10 amino acids in the N-terminal of TPH1 (T1) in HSP70 
interaction. B, When transiently overexpressed in HEK293 cells, both 
T1 mutant constructs exhibited increased expression as compared to 
HA-TPH2. HA-TPH2-T1E was expressed more efficiently, and also 
displayed increased HSP70 interaction, as compared to HA-TPH2-T1S. 
C, Quantification of the extents of HSP70 interaction with HA-TPH2, 
HA-TPH2-T1E and HA-TPH2-T1S. Band intensities of HSP70 were 
normalized to that of the HA-tagged substrates in the IP fractions, and 
presented as a ratio to HSP70 interaction with HA-TPH2. **, p < 0.05 
compared to HSP70 interaction with HA-TPH2; #, p < 0.05 compared 
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T1E exhibiting slightly higher expression as compared to HA-TPH2-
T1S (Figure 2.3B). Furthermore, quantification of HSP70 interaction 
revealed that HA-TPH2-T1E was able to interact with HSP70 more 
strongly as compared to HA-TPH2 or HA-TPH2-T1S (Figure 2.3C). As 
such, these observations further supported the notion that T1 could 
play a role in HSP70 interaction. Interaction between TPH2 and HSP70 
may be weaker as T1 is not fully conserved in TPH2. Furthermore, the 
corresponding amino acids to T1 on TPH2 are found after the N-
terminal 41 amino acids unique to TPH2, which could prevent 
interaction with HSP70 as a result of protein folding. 
 
2.3.3 Pharmacological inhibition of HSP70 decreases both TPH1 
and TPH2 expression  
In order to study the role of HSP70 in regulating TPH1 and 
TPH2 in vitro, we used the stable HEK293 cells lines expressing HA-
TPH1 and HA-TPH2 that we have generated. These stable cell lines 
were treated with KNK437, which has been demonstrated to inhibit the 
transcriptional activation of HSP70 (Yokota, Kitahara et al. 2000). It 
was observed that expression of both TPH1 and TPH2 decreased after 
KNK437 treatment (Figure 2.4A). However, TPH2 expression 
decreased at a relatively faster rate as compared to that of TPH1 after 
the cells were treated with KNK437 over a period of 24 h (Figure 2.4, A 
and B). To determine whether the above effects of KNK437 can be  
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FIGURE 2.4. TPH2 is more sensitive to HSP70 inhibition as 
compared to TPH1. A, HEK293 cells stably expressing HA-TPH1 and 
HA-TPH2 were treated with KNK437 for up to 24 h. Western blot 
showed that TPH1 expression decreased at a slower rate compared to 
that of TPH2 in response to KNK437 treatment. B, Quantification of 
changes in TPH1 and TPH2 expression levels in HEK293 stable cells 
after KNK437 treatment over 24 h. Expression levels were normalized 
to actin and presented as a ratio to expression levels at the start of 
treatment; **, p < 0.05 compared to expression levels at the start of 
treatment. Data are means ± S.E. (n=3). C, Similar results were 
observed when PC12 cells, stably expressing HA-TPH1 and HA-TPH2, 
were treated with KNK437 over 48 h. D, Quantification of changes in 
TPH1 and TPH2 expression levels in PC12 stable cells treated with 
KNK437 over 48 h. Expression levels were normalized to actin and 
represented as a ratio to expression levels at the start of treatment; **, 
p < 0.05 compared to expression levels at the start of treatment. Data 
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FIGURE 2.5. HSP70 knockdown affected TPH2 expression but not 
TPH1. A, PC12 cells stably expressing HA-TPH1 and HA-TPH2 were 
transfected with two individual shRNA constructs against rat HSP70 
(shRNA 1 and shRNA 2). Control shRNA was constructed using 
identical vector backbone with H1 promoter, but without shRNA insert. 
Western blot revealed a significant decrease in TPH2 expression when 
HSP70 levels were reduced, although TPH1 levels remained relatively 
unchanged. B, Quantification of protein expression of TPH1 and TPH2 
in PC12 cells after shRNA knockdown of HSP70. TPH1 and TPH2 
expression levels were normalized to actin, and represented as a ratio 
to protein expression of control; **, p < 0.05 compared to control. Data 
are means ± S.E. (n=4). C, The reduction in TPH2 expression was 
rescued when shRNA transfected cells were subjected to a 2 h heat 
shock followed by a 4 h recovery period. However, TPH1 expression 
levels remained unchanged after heat shock and recovery. D, 
Quantification of protein expression of TPH1 and TPH2 after shRNA 
knockdown of HSP70, and after heat shock rescue. TPH1 and TPH2 
expression levels were normalized to actin, and shown as a ratio to 
protein expression without heat shock rescue; **, p < 0.05 compared to 
non-heat shocked expression. Data are means ± S.E. (n=4). 
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FIGURE 2.6. HSP70 knockdown reduced TPH2 activity. A, PC12 
cells transiently overexpressing doxycycline-inducible HA-TPH2, and 
shRNA against HSP70 (rHSP70 shRNA 2) or control shRNA, were 
exposed to 1 μg/ml doxycycline (Dox) 24 h after transfection. 
Doxycycline induction was performed for 18 h, after which the cells 
were collected for HPLC analyses. B, 5-HT levels induced by 
doxycycline treatment in PC12 cells were measured by HPLC, then 
normalized to cell number in each sample. **, p < 0.05 compared to 
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observed in another cell line, PC12 cells stably expressing HA-TPH1 
and HA-TPH2 were also generated. When the PC12 cells were treated 
with KNK437 over 48 h, we observed a similar decrease in TPH1 and 
TPH2 expression. However, TPH2 expression decreased significantly 
at a faster rate as compared to TPH1 (Figure 2.4, C and D). Our results 
thus indicated that TPH2 is more sensitive than TPH1 to changes in 
HSP70 levels in vitro, which in turn may be attributed to the weaker 
interaction between TPH2 and HSP70. 
 
2.3.4 HSP70 levels affect TPH2 expression and activity 
To further confirm the effects of pharmacological inhibition of 
HSP70 on TPH expression, and to determine the role of HSP70 in TPH 
regulation, we used shRNA against HSP70, thus allowing for more 
specific gene targeting and knockdown. It was observed that in stable 
PC12 cell lines transfected with two different shRNA constructs against 
HSP70, TPH2 expression levels were significantly reduced in both 
cases when HSP70 levels decreased. However, TPH1 expression 
levels exhibited very little changes when endogenous HSP70 was 
knocked down (Figure 2.5, A and B). 
 
The effects of HSP70 knockdown on TPH2 expression levels 
could be rescued with a 2 h heat shock treatment, followed by a 4 h 
recovery, which transiently increased endogenous HSP70 levels 
(Figure 2.5, C and D). We also observed that heat shock resulted in an 
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increase in TPH2 expression levels in mock knockdown cells, further 
suggesting that an increase in endogenous HSP70 levels would in turn 
increase the stability and expression of TPH2 in vitro (Figure 2.5, C 
and D). In addition to protein expression, we also examined the effects 
of HSP70 knockdown on TPH2 activity. To allow efficient control of HA-
TPH2 translation after HSP70 knockdown, PC12 cells were first 
transfected with doxycycline-inducible HA-TPH2 and HSP70 specific or 
control shRNA. The expression of HA-TPH2 was then induced in the 
transfected cells by the addition of doxycycline, and the levels of 5-HT 
produced after 18 h was assessed by HPLC (Figure 2.6A). From 
Figure 2.6B, 5-HT levels in HSP70 knocked down cells were observed 
to be about 30% lower as compared to cells with normal levels of 
HSP70, thus indicating that enzyme activity was also affected when 
HSP70 levels were reduced. This supported our earlier observations 
that HSP70 may play a role in stabilizing TPH2, thereby improving 
enzyme expression and activity. 
 
2.4 DISCUSSION 
The present study has revealed a novel in vitro interaction 
between HSP70 and both isoforms of TPH. Although densitometry 
quantifications did not yield significant results (Figure 2.1, D and F), 
there was a perceivable trend that TPH1 exhibited a stronger 
interaction with HSP70, as compared to the interaction between HSP70 
and TPH2. It was also demonstrated here that the T1 domain was 
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primarily responsible for HSP70 interaction in TPH1. However, the 
potential role of the subsequent residues within the TPH1 regulatory 
region in HSP70 interaction still requires further investigation. In 
addition, our results have suggested that amino acids 1-41 of TPH2 
may interfere with HSP70 interaction. Nevertheless, whether this effect 
was due to protein folding as we have proposed, still remains to be 
established. 
 
It was interesting to note that even though KNK437 treatment 
reduced TPH1 and TPH2 expression over time, HSP70 knockdown 
only affected TPH2 expression and activity. KNK437 is a small 
molecule that inhibits the binding of transcriptional activators, known as 
heat shock factors, to heat shock sequence elements, the upstream 
promoter sequences of heat shock genes (Ohnishi, Takahashi et al. 
2004). As most heat shock genes are regulated by heat shock factors, 
it is likely that the transcription of members of other heat shock protein 
families can also be inhibited during KNK437 treatment (Yokota, 
Kitahara et al. 2000; Ohnishi, Takahashi et al. 2004; Manwell and 
Heikkila 2007). Furthermore, other members of the 70 kDa heat shock 
protein family were also identified as potential interacting partners of 
TPH1 and TPH2 in this study. Since heat shock proteins are able to 
form functional complexes with other chaperones and co-chaperones 
from various heat shock proteins families (Young, Hoogenraad et al. 
2003; Meimaridou, Gooljar et al. 2009), it is plausible that HSP70 
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functions as part of a larger complex of other heat shock proteins that 
can work collectively to regulate the stability of TPH1 and TPH2. This 
may also lead to the identification of other potential interacting partners 
by MALDI-TOF/TOF MS, as we have observed in this study. 
Nevertheless, the potential partner proteins that we have identified 
have not been thoroughly investigated, and thus their role in the 
regulation of TPH1 and TPH2 stability could not be ruled out. Our 
observations from treating cells with KNK437 also supported this notion 
that additional chaperones from other heat shock proteins families may 
play a regulatory role, particularly in TPH1 expression and stability. 
These chaperones were not detected under the preparation and 
staining conditions of the samples in this study, possibly because they 
were present in low levels, or weak interactions might have resulted in 
dissociation from the heat shock complex. Further studies are required 
to identify these additional chaperones and determine the mechanism 
by which they function together with HSP70 to stabilize both isoforms 
of TPH. 
 
In comparison to KNK437 treatment, RNA interference is a more 
specific targeting strategy with less off target effects. While TPH1 
expression remained relatively unchanged when HSP70 was knocked 
down, a reduced TPH2 expression was observed. We postulated that 
this observation could be due to the stronger interaction between TPH1 
and HSP70. Since HSP70 knockdown efficiencies in this study were 
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limited as a result of the constraint in transfection efficiencies, residual 
levels of endogenous HSP70 might be already sufficient to maintain 
TPH1 stability and expression. In contrast, slight changes in HSP70 
levels would give rise to corresponding changes in TPH2 stability and 
activity as a result of weaker interaction between TPH2 and HSP70. 
Moreover, the identification of several other potential interacting 
partners of TPH1 by MALDI-TOF/TOF MS also presented the 
possibility that the role of HSP70 in stabilizing TPH1 could be 
compensated by other heat shock proteins when HSP70 was knocked 
down. On the other hand, this compensatory mechanism might be 
absent in TPH2 stabilization, indicating the specificity of the interaction 
between TPH2 and HSP70. 
 
Taken together, the findings in this study suggested that while 
HSP70 acted as a chaperone by stabilizing protein expression and 
activity of both TPH isoforms, its weaker interaction with TPH2 could 
give rise to an increased sensitivity in TPH2 expression and activity to 
changes in HSP70, thus increasing the instability of TPH2 in vitro. 
Unlike 14-3-3 proteins, which interact with and stabilize phosphorylated 
TPH2 (Winge, McKinney et al. 2008), the binding of HSP70 did not 
require any post-translational modifications. This suggests that the 
chaperone, as part of a larger heat shock complex, potentially acts on 
TPH2 as the protein is being translated. However, the binding is 
relatively weak due to a shielded and non-conserved interacting 
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domain on TPH2, which may result in protein misfolding and instability 
during translation. 
 
The dysregulation of brain 5-HT homeostasis and 
neurotransmission is associated with many neuropsychiatric disorders, 
such as depression, schizophrenia, and bipolar disorder (Lucki 1998). 
Since the discovery of TPH2 as the brain specific isoform of the rate-
limiting enzyme in 5-HT synthesis, polymorphisms of the TPH2 gene 
have been identified in cohorts of patients with psychiatric disorders 
(Zhang, Gainetdinov et al. 2005; Chen, Novak et al. 2006; Hong, 
Sugawara et al. 2007; Waider, Araragi et al. 2011). This suggests that 
in addition to signaling through serotonergic receptors, changes in 
TPH2 enzyme activity may also contribute to the symptoms associated 
with such disorders, thus making TPH2 a potential therapeutic target. It 
has become increasingly evident that several regulatory mechanisms 
exist to modulate TPH2 expression and activity, during transcription, 
post-transcription, translation, and post-translation (Kuhn, Sakowski et 
al. 2007; Chen, Vallender et al. 2008; Winge, McKinney et al. 2008; 
Grohmann, Hammer et al. 2010). This fine control of TPH2 activity may 
be crucial given the role of brain 5-HT in mood, behavior and cognition. 
Recent studies have also associated environmental stress with the 
regulation of TPH2 gene expression. Several studies observed an 
increase in TPH2 expression following stressful stimuli, which is known 
to elevate HSP70 levels (Zhang, Takahashi et al. 1994; Matz, 
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Sundaresan et al. 1996; Brown, Henderson et al. 2006; Sidor, Amath et 
al. 2010). However, conflicting findings have also reported that 
exposure to stressful events resulted in reduced TPH2 expression 
(Rahman and Thomas 2009; Own, Iqbal et al. 2013). This could be due 
to the tissue specific and species dependant nature of TPH2 
expression, as well as cross talk between multiple systemic and 
cellular components, which contribute to the complex signaling network 
that mediates the stress response (Clark, Pai et al. 2005; Malek, Sage 
et al. 2007; Heydendael and Jacobson 2009; Barr and Forster 2011). 
As the current study only investigated the role of HSP70 in TPH2 
expression in vitro, the functional significance of the interaction 
between TPH2 and HSP70, and possibly other heat shock proteins, 
should also be studied in vivo. Nevertheless, with low levels of HSP70 
and TPH2 present in the brain under non-stress conditions, in vivo 
interaction may be more difficult to detect (D'Souza and Brown 1998; 
Bodega, Hernández et al. 2002). Similarly, the role of HSP70 and other 
heat shock proteins in the regulation of TPH1 can also be further 
explored in peripheral tissues in vivo. 
 
Increased intracellular 5-HT levels have been observed after 
hyperthermic stress and ischemia (Lin 1997). As HSP70 expression is 
also induced by heat stress and ischemic conditions following traumatic 
brain injury (Brown, Rush et al. 1989; Dutcher, Underwood et al. 1998; 
Sharp, Massa et al. 1999), the current study proposes a potential 
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mechanism that can associate the increase in TPH2 activity at the 
cellular level and subsequent brain 5-HT production to the upregulation 
of HSP70 due to stressful stimuli. While increased 5-HT levels in the 
brain after injury can give rise to both beneficial and detrimental effects 
that are still not fully understood, there is increasing evidence that 5-HT 
is able to induce adult neurogenesis (Brezun and Daszuta 1999; 
Brezun and Daszuta 2000; Malberg, Eisch et al. 2000; Banasr, Hery et 
al. 2003). This in turn suggests that 5-HT may be involved in cellular 
and functional repair. Indeed, antidepressants such as fluoxetine, 
which can increase tissue levels of 5-HT, have been shown to improve 
cognitive and motor functions, and also have anti-inflammatory effects 
in post-ischemic rats (Li, Cai et al. 2009; Lim, Kim et al. 2009). Thus, 
the stabilization of TPH2 by HSP70 as demonstrated in this study may 
also provide a possible molecular mechanism of functional repair to 
damaged neurons in the early stages of stress following acquired brain 
injury. Interestingly, exercise has also been shown to induce the 
increase in brain levels of HSP70 and 5-HT (Meeusen and De Meirleir 
1995; Gomez-Merino, Béquet et al. 2001; Liu, Yang et al. 2010). 
Although the functional link between HSP70 and 5-HT in exercise is 
still being speculated, the molecular regulation of TPH2 stability and 5-
HT production by HSP70 presented in this study may provide further 
insights into exercise endurance and fatigue (Heck, Schöler et al. 
2011). Despite these emerging indications, HSP70 may prove to be a 
difficult therapeutic target due to the promiscuous nature of its 
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interactions with proteins in both the central nervous system and 
periphery. Moreover, numerous serotonin receptors and transporters 
mediate serotonergic signaling in the brain, which may give rise to 
systemic effects that are complex to resolve in vivo. Nevertheless, the 
findings in this study can contribute new insights into the molecular 
regulation of TPH2 stability, and further highlight the neuroprotective 
role of HSP70 in the central nervous system.  
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3.  THE ROLE OF UBIQUITINATION IN REGULATING 
STABILITY OF TRYPTOPHAN HYDROXYLASE-2  
 
3.1 INTRODUCTION 
 The role of protein-protein interactions in the regulation of 
tryptophan hydroxylase-2 (TPH2) stability was explored in the previous 
chapter. Besides protein regulators, post-translational modifications 
can also provide an additional level of regulation to allow fine control of 
TPH2 expression and activity in the brain.  
 
Tryptophan hydroxylases (TPH) catalyze the first and rate-
limiting step in the biosynthesis of serotonin (5-HT). Previously 
considered as a single enzyme, it is now understood that two isoforms 
exist. Tryptophan hydroxylase-1 (TPH1) controls 5-HT levels in 
peripheral tissues, while TPH2 regulates the production of 5-HT 
specifically within the central nervous system (Walther and Bader 
2003; Walther, Peter et al. 2003; Zhang, Beaulieu et al. 2004). 
Characterizations of TPH2 have revealed that the brain specific isoform 
has an elongated N-terminal regulatory domain, with an additional 41 
amino acids that are absent in TPH1 (Walther and Bader 2003; 
Murphy, Zhang et al. 2008). This extended regulatory domain appears 
to exert a negative regulatory effect on TPH2, decreasing enzyme 
solubility and stability in vitro, in comparison to TPH1 (Carkaci-Salli, 
Flanagan et al. 2006; Murphy, Zhang et al. 2008). The lower 
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expression levels of TPH2 observed in mammalian cells is also 
attributed to a faster rate of degradation, compared to TPH1 (Murphy, 
Zhang et al. 2008). Although the two TPH isoforms exhibit distinctive 
characteristics, both TPH1 and TPH2 can be phosphorylated, similar to 
other aromatic amino acid hydroxylases (Fitzpatrick 1999). 
Phosphorylation increases TPH1 and TPH2 solubility, expression and 
stability in vitro (McKinney, Knappskog et al. 2005; Murphy, Zhang et 
al. 2008). Phosphorylated TPH2 has also been demonstrated to 
interact with 14-3-3 proteins, which in turn act to stabilize the enzyme 
(Winge, McKinney et al. 2008). Even though the role of 
phosphorylation in the regulation of both TPH isoforms has been 
extensively studied, it is currently still unclear whether post-
translational modifications can contribute to the differences in stability 
that were observed between TPH1 and TPH2 in vitro. Nevertheless, 
the faster rate of degradation of TPH2 may point to the presence of 
other post-translational modifications in TPH2 that can result in a 
higher turnover rate as compared to TPH1. 
 
 Protein degradation in the cell occurs through two major 
mechanisms, autophagy and ubiquitination. Autophagy involves the 
lysosomal degradation of large proteins and organelles by proteases 
and hydrolases upon the fusion of autophagocytic vesicles with 
lysosomes. In contrast, proteasomal degradation is an active process 
that mediates the degradation of most cytosolic proteins (Cooper 
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2000). Proteins broken down through the proteasomal pathway 
undergo ubiquitination, which is a post-translational modification 
process. Ubiquitin is bound onto specific lysine residues of a substrate 
protein through an ubiquitination cascade involving three types of 
enzymes, E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating 
enzymes, and E3 ubiquitin ligases. The resulting poly-ubiquitin chains 
on the substrate proteins are then able to act as a degradation signal, 
allowing the transportation of these ubiquitinated proteins to the 26S 
proteasome, where they are unfolded and broken down (Hershko and 
Ciechanover 1992; Jentsch 1992). The ubiquitin-proteasome system 
has been demonstrated to play a role in several neurodegenerative and 
neurological disorders (Yi and Ehlers 2007; Dennissen, Kholod et al. 
2012), and recently has also been implicated in neuropsychiatric 
disorders, such as schizophrenia and bipolar disorders (Bousman, 
Chana et al. 2010; Rubio, Wood et al. 2013).  
 
 While TPH1 has been reported to undergo ubiquitination 
(Kojima, Oguro et al. 2000), the degradation mechanism of TPH2 is still 
not well understood. Given that TPH2 is less stable in vitro than TPH1, 
it is plausible that TPH2 is more heavily ubiquitinated, thus giving rise 
to a more rapid degradation rate. This present study used a cell culture 
system to examine the notion of TPH2 ubiquitination, as well as 
employed site-directed mutagenesis to seek to identify potential 
ubiquitination sites. The results suggested that heavy ubiquitination 
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and the subsequent proteolysis of TPH2 could contribute to enzyme 
instability in vitro. Furthermore, our findings also indicated that 
ubiquitination could occur in the absence of lysine residues, pointing to 
the potential involvement of alternative mechanisms that could facilitate 
TPH2 ubiquitination. 
 
3.2 EXPERIMENTAL PROCEDURES 
3.2.1 Cell culture and reagents  
PC12 cells and all stable PC12 cell lines were grown in 
Dulbeccoʼs modified Eagleʼs medium, supplemented with 10% horse 
serum (Gibco, Life Technologies) and 5% bovine calf serum (HyClone, 
Thermo Scientific). A stock solution of 10 mM N-
[(Phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-L-
leucinamide (MG132, Tocris Bioscience) was made in dimethyl 
sulfoxide. Dimethyl sulfoxide was used as a control for all MG132 
treatments. 
 
3.2.2 Molecular reagents and transfection 
Cells were transiently transfected either by electroporation, at 
300 V and 1000 μF using a Gene Pulser II (Bio-Rad), or by 
Lipofectamine 2000 (Life Technologies) according to manufacturerʼs 
instructions. In order to allow for efficient detection of overexpressed 
proteins, all constructs used in this study were cloned into the 
	   68	  
pcDNA3.1 vector (Invitrogen), with either a triple hemagglutinin (HA) 
tag or DYKDDDDK (FLAG) tag at the N-terminus. Human ubiquitin 
(NM_018955) was amplified from total cDNA of HEK293 cells by PCR. 
Single lysine to arginine site-directed mutagenesis was performed 
using the primers presented in Table 2. KR mutagenesis constructs 
consisting of multiple lysine to arginine substitutions were generated 
using synthetic gBlocks gene fragments (Integrated DNA 
Technologies), except HA-K11-116R and HA-K11-183R which were 
generated using primers in Table 3.2. All clones generated were 
verified by sequencing.  
 
















Codons corresponding to substituted lysine residues are highlighted in 
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3.2.3 Immunoprecipitation 
48 h after transfection and 8 h after MG132 treatment, PC12 
cells were collected and homogenized in lysis buffer (20 mM Tris, 150 
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton-X100) with 5 mM 
phenylmethylsulfonyl fluoride (Sigma-Aldrich) and 1x Complete EDTA-
free protease inhibitor (Roche), by a pellet homogenizer (Kontes, 
Fisher Scientific).  Cell lysates were separated by centrifugation at 
13200 rpm for 10 min at 4°C, before supernatants were incubated with 
anti-HA agarose (Sigma-Aldrich) overnight at 4°C with rotation. Beads 
were washed intensively with lysis buffer. Proteins were then eluted by 
the addition of 1x Laemmli buffer containing 10% β-mercaptoethanol, 
followed by heating at 55°C for 20 min. Samples were heated at 55°C 
for 15 min before equal volumes were resolved by electrophoresis for 
Western blotting, as described below. 
 
3.2.4 Western blotting  
PC12 cells were collected and lysed in RIPA buffer (50 mM Tris, 
150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 1% sodium 
deoxycholate, 0.1% SDS), with the addition of 5 mM 
phenylmethylsulfonyl fluoride (Sigma-Aldrich) and 1x Complete EDTA-
free protease inhibitor (Roche). Lysates were then centrifuged at 13200 
rpm for 10 min at 4°C to obtain soluble proteins. All cell lysates 
obtained were quantified using DC protein assay kit (Bio-Rad), and 
diluted in 2x Laemmli sample buffer with 10% β-mercaptoethanol. 
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Protein samples were heated at 55°C for 15 min before being resolved 
on 10% SDS-PAGE. Transfers onto nitrocellulose membranes were 
performed using the Mini Trans-Blot Module (Bio-Rad). HA-tagged 
proteins were examined using anti-HA antibody (Covance Inc.), while 
FLAG-tagged proteins were analyzed using anti-FLAG M2-Peroxidase 
(Sigma-Aldrich). Anti-actin (Millipore) was used as control. All 
immunoblots were incubated with primary antibodies at 4°C overnight. 
Membranes were incubated with horseradish peroxidase conjugated 
goat anti-mouse secondary antibodies (Pierce, Thermo Scientific), 
when non-peroxidase conjugated primary antibodies were used. All 
blots were then detected using SuperSignal West Pico 
Chemiluminescent Substrate kit (Pierce, Thermo Scientific), with 
Fujifilm Super RX-N film or ImageQuant LAS 4000 Biomolecular 
Imager (GE Healthcare). Band intensities from at least three 
independent experiments were used for quantification of protein 
expression levels, using ImageJ software (Version 1.43u, National 
Institutes of Health).  
 
3.2.5 Bioinformatics and statistical analyses 
Prediction of ubiquitination sites was performed using online 
predictors UbPred ((Radivojac, Vacic et al. 2010), 
http://www.ubpred.org/), BDM-PUB 
(http://bdmpub.biocuckoo.org/index.php) and hCKSAAP_UbSite 
((Chen, Zhou et al. 2013), 
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http://protein.cau.edu.cn/cksaap_ubsite/index.php). ClustalW2 (EMBL-
EBI) was used to carry out protein sequence alignment. Studentʼs two-
tailed t test was applied to compare the protein expression of TPH1 
and TPH2 with and without MG132 treatment, and the differences in 
protein expression between TPH2 and the lysine-less TPH2 mutant. 
Differences in protein expression levels of wild type TPH2 and lysine to 
arginine mutants were compared using analysis of variance with 
Tukeyʼs post hoc analysis. Statistical significance was recognized 
when p < 0.05. GraphPad Prism (Version 5.0d, GraphPad Software) 
was used to perform statistical analyses and plot all graphs. 
 
3.3 RESULTS 
3.3.1 TPH2 expression is regulated by the proteasome 
  As proteasome inhibitors allow the accumulation of 
ubiquitinated proteins by preventing proteosomal function, the 
proteasome inhibitor MG132 was used to investigate the role of the 
ubiquitin-proteasome system in the degradation of TPH2. PC12 cells 
stably expressing HA-tagged TPH2 were treated with 1 μM MG132 for 
8 h. The cells were then harvested, and TPH2 expression levels were 
analyzed. TPH2 expression level was observed to increase 
significantly after MG132 treatment (Figure 3.1, A and B). Similarly, 
when transiently overexpressed in PC12 cells, TPH2 protein levels also 
increased after MG132 treatment (Figure 3.1, C and D). In addition to 
the rise in protein expression levels, higher molecular weight bands 
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were also detected when cells expressing TPH2 were exposed to 
MG132. These bands appeared to increase in multiples of 
approximately 8 kDa, which corresponded to the size of ubiquitin 
(Figure 3.1, A and C). TPH1 expression also increased after MG132 
treatment, albeit to a smaller extent compared to TPH2. However, the 
distinct higher molecular weight bands were not detected in MG132 
treated cells transiently expressing TPH1 (Figure 3.1C). Thus, the 
results suggested that the degradation of TPH2 could occur through a 
proteasome dependent pathway.   
 
3.3.2 TPH2 is highly ubiquitinated compared to TPH1 
 Protein targeting by ubiquitination is required for proteasomal 
degradation. As such, we sought to determine whether TPH2 could be 
ubiquitinated. Human ubiquitin (Ub) was cloned and fused with a HA or 
FLAG tag at its N-terminus. PC12 cells were then transiently 
transfected with HA-tagged TPH2 together with FLAG-tagged Ub, or 
FLAG-tagged TPH2 with HA-tagged Ub. The transfected PC12 cells 
were then treated with MG132 for 8 h, and cell lysates were subjected 
to immunoprecipitation using HA agarose. As demonstrated in Figure 
3.2A, FLAG-Ub was co-immunoprecipitated with HA-TPH2 in MG132 
treated cells, but not in the DMSO treated controls. A reciprocal 
immunoprecipitation of HA-Ub also revealed that FLAG-TPH2 was 
associated with ubiquitin in the presence of MG132, thus indicating that 
TPH2 was able to undergo ubiquitination in PC12 cells. 
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FIGURE 3.1. TPH2 expression is stabilized by proteasomal 
inhibition. A, PC12 cells stably expressing HA-TPH2 were treated with 
1 μM MG132 for 8 h. Western blot revealed an increase in TPH2 
protein expression after MG132 treatment, together with distinct bands 
of higher molecular weight that were increasing in multiples of 
approximately 8 kDa (arrowheads). B, Quantification of protein 
expression of TPH2 in PC12 stable cells with or without MG132 
treatment. TPH2 expression levels were normalized to actin, and 
presented as a ratio to protein expression of DMSO treated sample; **, 
p < 0.05 compared to DMSO treated sample. Data are means ± S.E. 
(n=3). C, In transiently transfected PC12 cells, a similar increase in HA-
TPH2 protein expression was observed in MG132 treated cells, in 
addition to the presence of higher molecular weight bands 
(arrowheads). HA-TPH1 expression also increased marginally with 
MG132 treatment, but higher molecular weight bands were not 
observed. 30 μg of HA-TPH1 expressing cell lysates and 50 μg of HA-
TPH2 expressing cell lysates were loaded on SDS-PAGE for Western 
blot. D, Quantification of protein expression of TPH1 and TPH2, with or 
without MG132 treatment. TPH1 and TPH2 expression levels were 
normalized to actin, and shown as a ratio to protein expression of 
DMSO treated samples; **, p < 0.05 compared to DMSO treated 









FIGURE 3.2. TPH2 is ubiquitinated more heavily as compared to 
TPH1. A, PC12 cells were transiently transfected with HA-TPH2 and 
FLAG-Ub, or FLAG-TPH2 and HA-Ub. Lysates were 
immunoprecipitated (IP) with HA agarose beads and separated 
fractions were detected using anti-FLAG on Western blot. FLAG-Ub 
was observed to associate with HA-TPH2 in MG132 treated cells. 
Reciprocal IP of HA-Ub also co-immunoprecipitated FLAG-TPH2 in 
cells treated with MG132. As TPH2 monomers can tetramerize in vitro, 
a transient co-transfection of HA-TPH2 and FLAG-TPH2 served as a 
positive control. B, FLAG-Ub was similarly co-transfected in PC12 cells 
with HA-TPH2, HA-TPH1 or chimeric HA-1-41-TPH1, and transfected 
cells were subjected to MG132 treatment. Subsequent IP and Western 
blot revealed that TPH2 strongly interacted with FLAG-Ub, as 
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To further investigate the extent of TPH2 ubiquitination in 
comparison to TPH1, HA-tagged TPH1 and TPH2 were transiently 
overexpressed in PC12 cells, together with FLAG-Ub. In addition, the 
role of the first 41 amino acids unique to TPH2 in ubiquitination was 
examined, using a HA-tagged chimeric construct that consisted of the 
first 41 amino acids of TPH2 added to the N-terminal of TPH1 (HA-1-
41-TPH1, Figure 3.2B). This chimeric protein was also co-expressed in 
PC12 cells together with FLAG-Ub. Cells were incubated in the 
presence or absence of MG132 for 8 h, and lysates were then 
immunoprecipitated using HA agarose. When the immunoprecipitated 
fractions were analyzed by Western blot, it was noted that while FLAG-
Ub interacted with HA-TPH2 in MG132 treated cells, very low amounts 
of FLAG-Ub was co-immunoprecipitated with HA-TPH1 and HA-1-41-
TPH1, even after MG132 treatment (Figure 3.2B). This suggested that 
TPH2 was more heavily ubiquitinated compared to TPH1, and also 
indicated that the bulk of TPH2 ubiquitination did not occur on the first 
41 amino acids of its N-terminal regulatory domain. 
 
3.3.3 Regulatory and catalytic domains of TPH2 can be 
ubiquitinated 
 As the N-terminal regulatory domains of TPH1 and TPH2 were 
not conserved, the variation in amino acid sequences may also result 
in differential ubiquitination and enzyme stability. We identified six 
lysine residues in the regulatory domain of TPH2 that were not 
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conserved in TPH1 (Figure 3.3A), which could be potential sites of 
ubiquitination. In order to examine the roles of these non-conserved 
lysine residues in the regulation of TPH2 degradation, site-directed 
mutagenesis was performed to replace these six lysine residues with 
arginine. HA-tagged mutant constructs with single lysine to arginine 
substitutions (K11R, K38R, K43R, K54R, K63R and K116R), as well as 
K11-116R where all six lysine residues were replaced, were then 
transiently expressed in PC12 cells to determine protein expression 
and extent of ubiquitination. The expression levels of all substitution 
mutants were observed to be similar to wild type TPH2 (Figure 3.3, B 
and C). Furthermore, all mutants also associated with FLAG-Ub in a 
similar manner to wild type TPH2, when overexpressed together with 
FLAG-Ub in MG132 treated PC12 cells (Figure 3.3D). This suggested 
that other lysine residues, rather than the six non-conserved lysine 
residues identified, could be responsible for the ubiquitination of TPH2. 
 
 Taking into consideration that TPH2 has thirty-five lysine 
residues amongst its entire amino acid sequence, narrowing down the 
regions of ubiquitination may facilitate the process of identifying 
ubiquitinated lysine residues. Thus, the ubiquitination of the regulatory 
and catalytic domains of TPH2 was investigated. HA-tagged constructs 
of the TPH2 N-terminal regulatory domain (HA-N150), as well as a 
truncated TPH2 with no regulatory domain (HA-ΔN150-TPH2), were  
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FIGURE 3.3. Mutagenesis of non-conserved lysine residues in the 
TPH2 regulatory domain did not prevent ubiquitination. A, Protein 
sequence alignment of both TPH1 and TPH2 N-terminal regulatory 
domains revealed six lysine residues that are not conserved between 
the two isoforms (highlighted in red). B, Site-directed mutagenesis was 
performed at the six sites to generate individual HA-tagged lysine to 
arginine mutants (K11R, K38R, K43R, K54R, K63R and K116R), as 
well as a mutant with all six lysines substituted with arginine residues 
(K11-116R). Mutagenesis constructs were transiently transfected into 
PC12 cells, and expression levels were assessed by Western blot. C, 
Quantification of expression levels of all mutagenesis constructs when 
overexpressed in PC12 cells. Expression levels were normalized to 
actin, and represented as a ratio to protein expression of wild type 
TPH2. Data are means ± S.E. (n=3). D, All mutagenesis constructs 
were co-expressed with FLAG-Ub in PC12 cells, which were then 
treated with MG132. IP and Western blot showed that FLAG-Ub could 









	   78	  
FIGURE 3.4. Determining ubiquitinated domains on TPH2. A, HA-
tagged truncation mutants of the TPH2 catalytic and C-terminal 
tetramerization domains (HA-ΔN150-TPH2), as well as N-terminal 
regulatory domain (HA-N150) were generated. B, When co-expressed 
in PC12 cells with FLAG-Ub and exposed to MG132 treatment, both 
HA-ΔN150-TPH2 and HA-N150 were observed to co-
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generated (Figure 3.4A). These constructs were transiently co-
expressed with FLAG-Ub in PC12 cells, which were then treated with 
MG132 before cell lysates were subjected to immunoprecipitation using 
HA agarose. From Figure 3.4B, expression levels of both HA-N150 and 
HA-ΔN150-TPH2 was observed to increase after MG132 treatment, 
similar to TPH2. In addition, FLAG-Ub also associated with both HA-
N150 and HA-ΔN150-TPH2 in the presence of MG132, suggesting that 
multiple ubiquitination sites were present in both the regulatory and 
catalytic domains of TPH2.  
 
 Since multiple ubiquitination sites could be present on TPH2, 
prediction software was employed to analyze the TPH2 amino acid 
sequence for potential ubiquitination sites. Two predictors with different 
algorithms for prediction were used. While the predicted sites varied 
between the two predictors, lysine residue K183 was found to be a 
common predicted ubiquitination site, in addition to K54 and K63, 
which have been previously identified (Table 3.2). As such, we 
generated an additional HA-tagged mutant construct, where the seven 
identified lysine residues, including K183, were replaced with arginine 
(HA-TPH2-K11-183R, Figure 3.5A). When transiently transfected in 
PC12 cells, the expression of HA-TPH2-K11-183R was relatively 
unchanged compared to wild type TPH2 and HA-TPH2-K11-116R 
(Figure 3.5, B and C). Moreover, HA-TPH2-K11-183R associated with 
FLAG-Ub when both constructs were co-expressed in MG132 treated 
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PC12 cells (Figure 3.5F). To further understand how these seven 
lysine-to-arginine mutations affect changes in expression and 
ubiquitination in the regulatory and catalytic domains, they were 
introduced into HA-N150 and HA-ΔN150-TPH2 at their respective 
positions to generate HA-N150-K11-116R and HA-ΔN150-TPH2-
K183R (Figure 3.5A). These mutant constructs were transiently 
expressed in PC12 cells and their expressions were analyzed. A 
discernible trend was observed, where HA-N150-K11-116R displayed 
higher expression levels compared to HA-N150, while HA-ΔN150-
TPH2-K183R exhibited lower expression compared to HA-ΔN150-
TPH2 (Figure 3.5, D and E). Nevertheless, both HA-N150-K11-116R 
and HA-ΔN150-TPH2-K183R were able to interact with FLAG-Ub when 
constructs were overexpressed in MG132 treated PC12 cells (Figure 
3.5F). Taken together, the data presented in this section indicated that 
mutation of K11, K38, K43, K54, K63, K116 and K183 were not 
sufficient to abolish ubiquitination and proteasomal degradation of 
TPH2. This in turn suggested that ubiquitination could occur on 
numerous sites located in both the regulatory and catalytic domains of 
TPH2. 
 
3.3.4 Ubiquitination of TPH2 could occur in the absence of lysine 
residues  
 As previously mentioned, TPH2 has thirty-five lysine residues 
found along its amino acid sequence. Although site-directed 
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mutagenesis could be used to study the roles of each lysine residue in 
TPH2 ubiquitination, individual or combinational lysine-to-arginine 
substitutions could prove to be time-consuming. Furthermore, there 
have been earlier indications that multiple ubiquitination sites were 
present on TPH2, and the removal of a single lysine residue could 
result in compensation of its function by other non-substituted lysine 
residues. As such, replacing all thirty-five lysine residues with arginine 
could facilitate the determination of the role of these lysine residues in 
TPH2 ubiquitination. A lysine-less mutant TPH2 with all thirty-five lysine 
residues substituted with arginine was generated, and the HA-tag was 
appended to its N-terminus (HA-TPH2-KR490, Figure 3.6A). When 
overexpressed in PC12 cells, HA-TPH2-KR490 was found to have 
lower levels of expression, as well as migrate at a faster rate on SDS-
PAGE, compared to wild type TPH2 (Figure 3.6, B and C). However, 
FLAG-Ub also co-immunoprecipitated with HA-TPH2-KR490, when 
both constructs were transiently expressed in MG132 treated PC12 
cells (Figure 3.6D), which suggested that ubiquitination could occur on 
TPH2 even in the absence of lysine residues. 
 
3.4 DISCUSSION  
 In this study, we investigated the mechanism of TPH2 
degradation that could contribute to its instability in vitro, as well as 
search for sites on TPH2 that play a role in protein turnover. Similar to  
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Two predictors were used for predication of ubiquitination sites on 
TPH2. Algorithms and threshold scores differed depending on the 
predictor used. UbPred identified 4 potential ubiquitination sites, with 
medium (0.69 ≤ Score ≤ 0.84) and high confidence (0.84 ≤ Score ≤ 
1.00). BDM-PUB prediction identified 11 potential ubiquitination sites 
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FIGURE 3.5. Non-conserved N-terminal lysines and predicted 
K183 did not affect ubiquitination of TPH2 domains. A, Lysine to 
arginine mutagenesis of K183 (K183R) was incorporated into existing 
HA-tagged K11-116R construct to generate HA-TPH2-K11-183R. All 
seven lysine to arginine substitutions were also introduced at their 
respective positions on HA-N150 and HA-ΔN150-TPH2 to generate 
HA-N150-K11-116R and HA-ΔN150-TPH2-K183R, respectively. B and 
D, All mutagenesis as well as wild type HA-tagged constructs were 
transiently expressed in PC12 cells, and expression levels were 
determined by Western blot. C and E, Quantification of expression 
levels of all mutagenesis constructs when overexpressed in PC12 
cells. Expression levels were normalized to actin, and represented as a 
ratio to protein expression of wild type TPH2; #, p < 0.05 when 
compared to HA-N150-K11-116R.  Data are means ± S.E. (n=3). F, All 
mutagenesis constructs were also co-expressed with FLAG-Ub in 
PC12 cells. In the presence of MG132, all transiently expressed 
proteins were observed to co-immunoprecipitate with FLAG-Ub, 
indicating that K11, K38, K43, K54, K63, K116 and K183 are not 
sufficient to cause TPH2 ubiquitination. 
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FIGURE 3.6. Lysine-less TPH2 could still conjugate to ubiquitin in 
vitro. A, Lysine-less TPH2, with all thirty-five lysines replaced with 
arginine residues, was synthetically generated and fused with a HA-tag 
at the N-terminus to construct HA-TPH2-KR490. B, Both wild type HA-
TPH2 and HA-TPH2-KR490 were transiently overexpressed in PC12 
cells. Expression levels were then examined using Western blot. C, 
Densitometric quantification of expression levels of HA-TPH2 and HA-
TPH2-KR490 when overexpressed in PC12 cells. Expression levels 
were normalized to actin, and represented as a ratio to protein 
expression of wild type HA-TPH2; **, p < 0.05 compared to expression 
levels of HA-TPH2. Data are means ± S.E. (n=3). D, Wild type HA-
TPH2 and HA-TPH2-KR490 were also co-expressed with FLAG-Ub in 
PC12 cells, which were then treated with MG132. IP and Western blot 
showed that HA-TPH2-KR490 could still associate with FLAG-Ub, 
despite the absence of lysine residues. 
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the previous chapter, PC12 cells were employed for the present study 
because they possessed neural characteristics, and also provided an 
efficient overexpression system for examining the degree of 
ubiquitination of TPH2 and its mutants under physiological conditions. 
We have showed that by inhibiting proteasomal degradation using 
MG132, TPH2 expression was significantly increased in PC12 cells 
that were stably or transiently expressing HA-TPH2. This is also the 
first report demonstrating that TPH2 could be heavily ubiquitinated. In 
contrast to earlier reports, little ubiquitination was detected on TPH1, 
although the increase in protein expression levels were similar to that 
previously described (Kojima, Oguro et al. 2000). The varying 
observations could be due to the differences in cell lines and protein 
expression techniques used. In this study, HA- and FLAG-tagged 
constructs were overexpressed in cells, since effective monoclonal 
antibodies against TPH2 were unavailable. Ubiquitination of TPH1 
could still be detected in cells treated with MG132, albeit only at longer 
exposures (data not shown). This in turn also indicated that TPH2 
could undergo ubiquitination more readily than TPH1, thus resulting in 
increased instability in vitro. 
 
 Although TPH2 ubiquitination and the involvement of 
proteasomal degradation have been demonstrated, the underlying 
mechanisms that gave rise to the differences in stability and extents of 
ubiquitination between TPH1 and TPH2 were still unknown. We initially 
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hypothesized that the differences in amino acid sequences, especially 
in the regulatory domains of both isoforms, could contribute to the 
differential ubiquitination and turnover rates. However, when non-
conserved lysine residues in the TPH2 regulatory domain were 
substituted to arginine, immunoprecipitation revealed that TPH2 was 
still ubiquitinated. Mutation of possible ubiquination sites predicted by 
prediction software (i.e. K183) also failed to abolish TPH2 
ubiquitination. This could be attributed to the limitations of the 
prediction software. UbPred and BDM-PUB were the software readily 
available when prediction was performed. These predictors were based 
on limited data sets obtained from experimental studies as well as 
literature mining (Li, Gao et al. 2009; Radivojac, Vacic et al. 2010). In 
addition, UbPred was built with a focus on ubiquitinated proteins in 
yeast. While functional categories of over-ubiquitinated proteins in 
yeast and human were demonstrated to be similar (Radivojac, Vacic et 
al. 2010), the prediction software could still have limitations due to 
small datasets and lack of specific consensus sequences for 
ubiquitination. This appeared to be the case for K183, since HA-TPH2-
K11-183R was still observed to be ubiquitinated.  
 
Recently, we analyzed the TPH2 amino acid sequence again 
using hCKSAAP_UbSite (Chen, Zhou et al. 2013), a more updated 
predictor based on a dataset of ubiquitinated human proteins. Seven 
positive prediction sites were revealed, but these sites were predicted 
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with low confidence and only one predicted lysine was located within 
the TPH2 regulatory domain (data not shown). The seven lysine 
residues that we originally identified were not presented as positive 
predicted sites by hCKSAAP_UbSite, which further supported our 
observations that lysine to arginine mutations of these seven residues 
still resulted in TPH2 ubiquitination. Although the seven newly 
predicted lysine residues could be further examined by similar 
mutagenesis techniques, the results are likely to be inconclusive. This 
is because in addition to demonstrating that both the regulatory and 
catalytic domains of TPH2 could be ubiquitinated, we have also shown 
that a lysine-less TPH2 could still undergo ubiquitination. These 
observations in turn suggested that TPH2 could be ubiquitinated via 
alternative mechanisms (Figure 3.7). 
 
Due to the absence of consensus sequences, protein 
ubiquitination sites can be diverse. Some proteins, like IκBα and 
receptor interacting protein kinase 1 (RIP1), are ubiquitinated through 
distinct lysine residues (Scherer, Brockman et al. 1995; Ea, Deng et al. 
2006). On the other hand, c-Jun can be ubiquitinated on any lysine 
residue along its amino acid sequence (Treier, Staszewski et al. 1994). 
Other proteins, such as Gcn4 and yeast uracil permease Fur4p, may 
be ubiquitinated at specific lysine residues that are proximal to an 
internal PEST degradation signal (Kornitzer, Raboy et al. 1994; 
Marchal, Haguenauer-Tsapis et al. 2000). In addition to internal 
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FIGURE 3.7. Possible mechanisms by which TPH2 can undergo 
ubiquitination and proteolysis. As lysine-less TPH2 was observed to 
be ubiquitinated, direct ubiquitination of TPH2 may occur through non-
canonical sites, such as serine, threonine and cysteine residues. We 
also postulated that TPH2 can be ubiquitinated indirectly, through 
interaction with additional protein partners (X). TPH2 may interact with 
proteins that can be ubiquitinated themselves, allowing the protein 
complex to be broken down in the proteasome. Alternatively, TPH2 
may contain UBDs that can also interact with ubiquitinated proteins, 
thereby facilitating proteasome degradation. Further studies will be 
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lysines, ubiquitination has been shown to occur at non-canonical sites 
as well. Several proteins have been reported to undergo N-terminal 
ubiquitination, whereby ubiquitin is conjugated linearly to the α-NH2 
group of the N-terminal methionine (Breitschopf, Bengal et al. 1998; 
Aviel, Winberg et al. 2000; Bloom, Amador et al. ; Coulombe, Rodier et 
al. 2004; Kuo, den Besten et al. 2004; Li, Okamoto et al. 2009; Vosper, 
McDowell et al. 2009; McDowell, Kucerova et al. 2010). Lysine-less 
mutants of these proteins could still be ubiquitinated and efficiently 
broken down as a result of this novel mechanism. Increased protein 
stability was also detected when the N-terminal methionine residues of 
these proteins were fused with a 6x-myc tag (Breitschopf, Bengal et al. 
1998; Aviel, Winberg et al. 2000; Bloom, Amador et al. 2003; Li, 
Okamoto et al. 2009; Vosper, McDowell et al. 2009). Similar 
observations were made in the case of TPH2, as we have shown in 
this study, where TPH2 ubiquitination did not require any lysine 
residues. Previous studies have also suggested that the addition of N-
terminal fusion tags could improve TPH2 stability in vitro (McKinney, 
Knappskog et al. 2004; McKinney, Knappskog et al. 2005). However, 
the presence of HA-tags at the N-terminus of HA-TPH2 and HA-TPH2-
KR490 could prevent ubiquitination of the N-terminal methionine. 
Protein expression levels of HA-TPH2-KR490 also unexpectedly 
decreased, unlike the unchanged protein levels observed in lysine-less 
mutants of N-terminal ubiquitinated proteins. Furthermore, HA-TPH2-
KR490 appeared to migrate faster than wild type HA-TPH2 during 
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electrophoresis, indicating lower molecular weight. While the underlying 
mechanisms giving rise to these observations were unknown, the 
decreased expression and molecular weight of HA-TPH2-KR490 could 
imply the involvement of other post-translational modifications in 
regulating TPH2 expression. Nevertheless, further studies would be 
required to examine this possibility. Apart from the N-terminal 
methionine, recent studies have also reported ubiquitination of internal 
serine, threonine and cysteine residues (Cadwell and Coscoy 2005; 
Tait, de Vries et al. 2007; Wang, Herr et al. 2007; Vosper, McDowell et 
al. 2009; McDowell, Kucerova et al. 2010). Nevertheless, such cases 
are uncommon and also require ubiquitin to form atypical ester linkages 
with serine and threonine residues, or thioester linkages with cysteine 
residues. Further investigations would be required in order to establish 
whether these non-canonical sites are involved in TPH2 ubiquitination 
and subsequent degradation.   
 
In addition to non-canonical ubiquitination sites, we postulated 
that the occurrence of TPH2 ubiquitination even in the absence of 
lysine residues could also be brought about protein-protein interactions. 
It is possible that TPH2 can interact with unknown protein partners that 
can undergo ubiquitination. As a result, ubiquitin will be detected to 
associate with TPH2 and the protein complex can subsequently be 
targeted for proteasomal degradation (Figure 3.7). Similarly, TPH2 may 
interact with other ubiquitinated proteins through ubiquitin binding 
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domains (UBDs), which are modular elements within proteins that can 
recognize and bind to ubiquitin non-covalently. UBDs can fold into a 
diversity of structural motifs, such as α-helices, zinc fingers, plekstrin 
homology folds, or ubiquitin conjugating domains, allowing interaction 
with ubiquitin to bring about functional outcomes like protein 
degradation (Hicke, Schubert et al. 2005; Dikic, Wakatsuki et al. 2009; 
Husnjak and Dikic 2012) (Figure 3.7). Taken together, the notion that 
additional interacting proteins are involved in TPH2 ubiquitination would 
imply that observations in this study were the result of indirect 
ubiquitination of TPH2, mediated through its association with 
ubiquitinated binding partners. Additional studies will be required in 
order to further explore these hypotheses, as well as identify any 
interacting partners and their roles in regulating TPH2 ubiquitination.  
 
Earlier studies have reported that aromatic amino acid 
hydroxylases, such as TPH1, tyrosine hydroxylase and phenylalanine 
hydroxylase (TH and PAH) could be ubiquitinated (Doskeland and 
Flatmark 1996; Kojima, Oguro et al. 2000; Doskeland and Flatmark 
2001; Doskeland and Flatmark 2002). However, ubiquitination sites 
have yet to be identified, although residues within the catalytic domain 
of PAH have been indicated to undergo ubiquitination (Doskeland and 
Flatmark 2001). Reports have also indicated that TPH1 and TH 
phosphorylation could trigger proteasomal degradation, suggesting that 
ubiquitination may be regulated by additional modifications (Iida, 
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Sawabe et al. 2002; Kawahata, Tokuoka et al. 2009; Nakashima, Mori 
et al. 2011). Nevertheless, the mechanisms by which phosphorylation 
could bring about TPH2 ubiquitination are still unknown. It is possible 
that phosphorylation can trigger conformational changes in TPH2, 
which may also improve its interaction with other protein partners that 
can bring about ubiquitination. However, this hypothesis still remains to 
be proven. While the findings of this study did not conclusively identify 
any ubiquitination sites on TPH2, the results have suggested that the 
difference in extent of ubiquitination between TPH1 and TPH2 is likely 
due to factors beyond the N-terminal regulatory domains alone. Further 
studies would be required to determine these regulatory factors and 
how they can give rise to the differential stabilities of TPH1 and TPH2. 
 
As TPH2 plays a crucial role in the production of brain serotonin, 
mutations leading to decreased TPH2 activity or stability have been 
implicated in a wide range of neuropsychiatric disorders (Zhang, 
Gainetdinov et al. 2005; Carkaci-Salli, Salli et al. 2014). Taking into 
consideration that TPH2 is less stable and experiences a faster 
turnover rate as compared to TPH1, studying the TPH2 degradation 
pathway and the regulatory factors involved may provide valuable 
insights to the development of new therapeutic interventions. The 
identification of ubiquitination sites or domains on TPH2 could thus 
provide a foundation to further the understanding of TPH2 proteolysis, 
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4.  DISCUSSION AND FUTURE DIRECTIONS  
 
4.1 DISCUSSION 
 Since the discovery of TPH2 as the neuron-specific isoform of 
the 5-HT synthesizing enzyme within the central nervous system 
(CNS), various studies have been performed on both molecular and 
systemic levels, to further understand regulation of this enzyme. Given 
that 5-HT can influence mood, sleep, learning and neural development, 
amongst others, dysregulation of brain 5-HT homeostasis can bring 
about detrimental effects. Indeed, disruption of serotonin signaling has 
been implicated in various neuropsychiatric disorders, such as 
depression, bipolar disorder, anxiety and schizophrenia (Lucki 1998; 
Zhang, Gainetdinov et al. 2005; Lin, Chao et al. 2007; Zhang, Li et al. 
2011; Berger, Weber et al. 2012).   
  
 Recent studies focused only on investigating transcriptional 
regulation of TPH2, and there is still a lack of studies pertaining to 
other regulatory factors that control TPH2 protein levels. Apart from the 
stabilizing functions of post-translational phosphorylation and 14-3-3 
proteins (Murphy, Zhang et al. 2008; Winge, McKinney et al. 2008), 
mechanisms resulting in the instability and degradation of TPH2 are 
still not well understood. Until now, it is only known that the N-terminal 
regulatory domain confers a destabilizing effect on TPH2 expression 
and activity, and that the formation of disulphide linkages could cause 
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TPH2 to misfold, inhibiting its catalytic activity and resulting in 
aggregate formation (Carkaci-Salli, Flanagan et al. 2006; Kuhn, Sykes 
et al. 2011). Therefore, the current work sought to elucidate regulatory 
mechanisms underlying this instability of TPH2. Specifically, we studied 
potential protein-protein interactions that can affect the stability of 
TPH2 in vitro, and also examined the role of ubiquitination and 
proteasomal degradation in TPH2 protein turnover. In both cases, our 
findings have revealed previously undiscovered aspects of TPH2 
regulation, which can form the basis of future studies.    
 
Improving the understanding of the regulation of TPH2 
expression and activity at the protein level may be important in the 
development of future therapeutic drugs, particularly in the treatment of 
neuropsychiatric illnesses. Currently available antidepressants, such as 
selective serotonin reuptake inhibitors (SSRIs) like fluoxetine, 
citalopram and paroxetine, act by blocking the serotonin transporter 
(SERT), which is present in both CNS and peripheral tissues. This may 
cause unanticipated side effects, arising as a result of SSRI action in 
the periphery. In comparison, TPH2 specifically controls synthesis of 
brain 5-HT, making it a therapeutic target that can potentially produce 
fewer side effects. Furthermore, TPH2 polymorphisms giving rise to 
missense mutations, such as P447R, have been shown to affect 
response to citalopram treatment (Cervo, Canetta et al. 2005). A recent 
study has also reported that chronic fluoxetine and paroxetine 
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treatment can worsen brain 5-HT deficiency in R439H Tph2 KI mice 
(Siesser, Sachs et al. 2013). Thus, a better understanding of TPH2 
regulation would be important to resolve these different responses to 
SSRI treatment. Characterization of TPH2 protein regulation can also 
reveal additional regulatory factors and protein interacting partners that 
may serve as novel therapeutic targets in neuropsychiatric treatment.    
  
4.2 FUTURE DIRECTIONS 
4.2.1 Heat shock proteins and other interacting partners of TPH2 
The identification of novel protein interacting partners of TPH2 
can give us new insights into the regulatory pathways involved in TPH2 
regulation. Differences in strengths of interactions as well as the 
identities of interacting partners associating with TPH1 and TPH2 can 
also allow us to infer the regulatory mechanisms giving rise to the 
different characteristics of both isoforms. The present study has 
demonstrated that although both TPH1 and TPH2 interact with HSP70, 
the weaker interaction detected between TPH2 and HSP70 could result 
in increased instability, as we have also shown that HSP70 has a 
stabilizing effect on TPH2 protein expression and activity. 
Nevertheless, in order to fully understand the role of HSP70 in relation 
to TPH2, and even TPH1, additional studies can be performed to 
support our current findings.  
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As our co-immunoprecipitation (IP) results indicated that HSP70 
could interact more strongly with TPH1 and weaker with TPH2, surface 
plasmon resonance (SPR) can be used to further support these 
observations. SPR allows for the measurement of binding affinity 
between unlabeled protein interacting partners. This will in turn 
circumvent the use of HA-tagged proteins in the current study, and also 
provides a more quantitative measure on strength of interaction 
between the binding partners. Our co-IP studies have also established 
that the first 10 amino acids of TPH1 were primarily involved in efficient 
HSP70 interaction. However, the underlying mechanisms by which this 
non-conserved stretch of amino acid residues gives rise to the 
differential extents of HSP70 interaction between TPH1 and TPH2 is 
still not understood. By using site-directed mutagenesis, co-IP and 
even SPR, the roles of these 10 amino acids on TPH1, and the 
corresponding residues on TPH2, can be further examined with respect 
to HSP70 interaction.  
 
We have demonstrated that the effects of HSP70 knockdown on 
TPH2 expression could be rescued by heat shock treatment followed 
by a short recovery period, which brought about an increase in 
endogenous HSP70. Nevertheless, overexpression of exogenous 
HSP70 will be a more specific approach for rescuing HSP70 
knockdown and should be performed to further reinforce the current 
observations. However, given that HSP70 plays a role in both protein 
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stabilization and proteolysis, transient overexpression of exogenous 
HSP70 may disrupt the relative stoichiometries of HSP70 and TPH2 
within the cells. Thus, optimization is first required to determine the 
amount of exogenous HSP70 to be transiently overexpressed in order 
to rescue the effects of HSP70 knockdown.  
 
On a similar note, increase in protein expression levels was not 
observed when exogenous HSP70 was transiently overexpressed in 
PC12 cells stably expressing HA-TPH2 (data not shown). We 
postulated that this could be due to the saturation of HSP70 binding 
sites, and therefore increasing HSP70 levels transiently would not 
affect TPH2 expression or stability further. Furthermore, transient 
overexpression of exogenous HSP70 may also disrupt the 
physiological levels of HSP70 within the cells, which in turn can lead to 
unexpected effects (as described above, and in (Roy, Li et al. 2005)). 
In order to overcome this, a stable knockdown or knockout cell line can 
be employed, such as PC12 cells with a stable knockdown of HSP70, 
or HSP70-/- mouse embryonic fibroblasts (MEFs). Overexpression of 
exogenous HSP70 in these cell lines will rescue the effects of lowered 
HSP70 levels on TPH2 expression and activity more effectively, 
although optimization of the amount of exogenous genes introduced 
may still be required.     
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As the scope of the current work was limited to in vitro studies, 
the role of HSP70 in relation to TPH2 activity and expression should 
also be investigated using in vivo models, such as knockout or knock-in 
mice. TPH2 expression and activity can be analyzed in brain tissue of 
HSP70 knockout mice, using Western blot and HPLC, to substantiate 
our in vitro data. In addition, potential behavioral changes can be 
assessed in these HSP70 knockout mice, which may result from 
changes in the levels and stability of TPH2 within the brain. Similarly, 
HSP70 expression can be induced in TPH2 knock-in mice, and 
changes in TPH2 levels, activity and effects on mouse behavior can 
then be investigated.  
 
Finally, the identification of HSP70 as a novel interacting partner 
of TPH1 and TPH2 also indicated that there could still be other 
potential interacting proteins that are yet to be uncovered. As the 
current study only identified interacting partners of approximately 70 
kDa, additional methods that do not impose a limit on molecular weight 
can be used to detect interacting proteins from whole cell lysate. Co-IP 
and 2D electrophoresis or 2D-difference gel electrophoresis (2D-DIGE) 
can be employed, which will separate interacting partners effectively. In 
the case of 2D-DIGE, comparisons between protein partners of TPH1 
and TPH2 can also be made. MALDI-TOF/TOF MS can then be used 
to analyze and identify interacting partners. Alternatively, whole IP 
fractions can also be directly subjected to trypsin digestion and MALDI-
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TOF/TOF MS identification. The detection of distinct interacting 
partners between TPH1 and TPH2 may indicate possible regulatory 
differences between the two isoforms, and thus can be further 
investigated. In this study, we have also identified potential interacting 
partners of TPH1 in HSP70Bʼ, HSC70 and HSPA1L. Although no 
further work was carried out on them, the interaction of the three 
identified proteins with TPH1 can be validated using co-IP and 
antibodies against endogenous proteins. RNA interference can also be 
employed to study the functions of these potential partners with respect 
to TPH1 regulation. 
 
4.2.2 Ubiquitination and TPH2 regulation 
 Understanding the mechanisms involved in TPH2 degradation 
and proteolysis may allow us to further appreciate the underlying 
causes that give rise to the instability of the enzyme. While the 
regulatory domain of TPH2 has been shown to play a role in 
destabilizing protein expression and activity, the subsequent pathway 
by which TPH2 is broken down, and whether the regulatory domain is 
involved, is still not well understood. We have demonstrated that TPH2 
could be heavily ubiquitinated and degraded via the proteasome. 
However, ubiquitination sites on TPH2 still remain elusive. In this 
section, we propose additional experiments that can be carried out to 
identify residues that can be modified by ubiquitination, which in turn 
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may allow us to further elucidate the degradation pathway and 
regulators involved. 
 
 Non-canonical ubiquitination has been implicated in TPH2 
degradation, since lysine-less TPH2 was observed to still be 
ubiquitinated. As such, the roles of atypical ubiquitination sites, such as 
serines, threonines and cysteines, should be further investigated. To 
examine the possibility of atypical ubiquitination sites, serine-less, 
threonine-less and cysteine-less TPH2 mutants can be generated 
using mutagenesis. Co-expression with FLAG-Ub and IP may then be 
used to assess the possibility of ubiquitination on these mutants. In 
addition, the role of phosphorylation in TPH2 ubiquitination can be 
further explored. To this end, mutagenesis of known TPH2 
phosphorylation sites, like S19 and S104, can be carried out, and the 
stability and ubiquitination of the mutants can be assessed. 
 
In this study, we utilized IP to detect ubiquitination sites, 
indicated by the association of exogenous FLAG-Ub with HA-tagged 
TPH2 and its mutants. Nevertheless, this approach requires generating 
numerous TPH2 mutants in order to narrow down potential 
ubiquitination sites, which can be fairly tedious and time-consuming. 
Methods such as liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) are increasingly gaining popularity due to the speed and 
efficiency in which ubiquitinated residues can be identified (Peng, 
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Schwartz et al. 2003; Coulombe, Rodier et al. 2004; Anania, Bustos et 
al. 2013). Thus, identification of ubiquitination sites is also possible 
using this approach. Furthermore, mass spectrometry can be 
employed to address the possibility of additional protein partners 
interacting with TPH2. Using co-IP, 2D-DIGE and MALDI-TOF/TOF 
MS, any potential interacting protein partners of HA-TPH2 during 
inhibition of proteasomal degradation may be identified and further 
studied. 
 
Lastly, the observation that TPH2 was ubiquitinated also 
indicates that an E1-E2-E3 ubiquitination cascade is catalyzing 
ubiquitin linkage to TPH2. As E3 ubiquitin ligases are able to recognize 
the specific target substrate(s) and catalyze the attachment of ubiquitin, 
identifying the E3 ligase involved in TPH2 ubiquitination may reveal a 
crucial regulator of TPH2 stability as well. Co-IP, MALDI-TOF/TOF MS, 
and yeast-two-hybrid are possible means by which the TPH2-specific 
E3 ligase can be determined. Alternatively, knockdown of known E3 
ligases using RNA interference may also be carried out in vitro to 
assess their effects on TPH2 expression.  
 
4.2.3 Conclusion 
 The results presented in this study have revealed a new TPH2-
interacting protein, as well as demonstrated the role of ubiquitination in 
TPH2 degradation. Our work has provided more insights to the 
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regulatory mechanisms underlying the instability of TPH2 at the protein 
level, which can be further supported by the additional studies 
illustrated in this chapter. This in turn can provide the basis for 
additional research that may further our understanding as to how the 
brain serotonergic system is being regulated at a molecular level. The 
new knowledge will also be able to contribute to the development of 
new therapeutics against neuropsychiatric conditions involving 5-HT 
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